**New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side-effect profile relative to established antipsychotics**

Maria C. Lobo\* 1-4, Thomas S. Whitehurst2-3, Stephen J. Kaar1,4, Oliver D. Howes1,3-5.

\*Corresponding author

1Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

2MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK

3Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK

4South London and Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK

5H. Lundbeck UK, Ottiliavej 9, 2500 Valby, Denmark

Corresponding author: Dr Maria C. Lobo, [maria.lobo@nhs.net](mailto:maria.lobo@nhs.net)

Psychosis Studies Department, 5th Floor, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, United Kingdom.

Co-authors: Dr Thomas S. Whitehurst, [t.whitehurst@lms.mrc.ac.uk](mailto:t.whitehurst@lms.mrc.ac.uk)

Dr Stephen J. Kaar, [stephen.kaar@kcl.ac.uk](mailto:stephen.kaar@kcl.ac.uk)

Professor Oliver D. Howes, [oliver.howes@kcl.ac.uk](mailto:oliver.howes@kcl.ac.uk)

Declaration of interest:

ML and TW report no conflicts of interest. SK received travel expenses for a scientific meeting from Autifony Ltd. OH is a part-time employee of H. Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatris/ Mylan. Neither OH or his family have holdings/ a financial stake in any pharmaceutical company. OH has a patent for the use of dopaminergic imaging.

Funding: This study was funded by Medical Research Council-UK (no. MC\_U120097115), Maudsley Charity (no. 666), and Wellcome Trust (no. 094849/Z/10/Z) grants to Dr Howes and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Abstract**

Schizophrenia is associated with substantial unmet needs, highlighting the necessity for new treatments. This narrative review compares the pharmacology, clinical trial data and tolerability of novel medications to representative antipsychotics. Cariprazine, brexpiprazole and brilaroxazine are partial dopamine agonists effective in acute relapse. Lumateperone (serotonin and dopamine receptor antagonist) additionally benefits asocial and depressive symptoms. F17464 (D3 antagonist and 5-HT1A partial agonist) has one positive phase II study. Lu AF35700 (dopamine and serotonin receptor antagonist) was tested in treatment-resistance with no positive results. Pimavanserin, roluperidone, ulotaront and xanomeline do not act directly on the D2 receptor at clinical doses. Initial studies indicate pimavanserin and roluperidone improve negative symptoms. Ulotaront and xanomeline showed efficacy for positive and negative symptoms of schizophrenia in phase II trials. BI 409306, BI 425809 and MK-8189 target glutamatergic dysfunction in schizophrenia, though of these only BI 425809 showed efficacy. These medications largely have favourable cardiometabolic side-effect profiles. Overall, the novel pharmacology, clinical trial and tolerability data indicate these compounds are promising new additions to the therapeutic arsenal.

**Keywords:** Schizophrenia, antipsychotic, cariprazine, brexpiprazole, lumateperone, pimavanserin, roluperidone, ulotaront, xanomeline, BI 425809, brilaroxazine, F17464

**Highlights:**

* Several new agents reduce psychotic symptoms without direct action on D2 receptors
* Cariprazine, pimavanserin and roluperidone may treat negative symptoms
* Some data suggest roluperidone, xanomeline and BI425809 improve cognitive symptoms
* Partial D2 agonists and low D2 affinity drugs could benefit treatment resistance
* Novel agents have low rates of both extra-pyramidal and metabolic side effects

**1. Introduction**

Schizophrenia is amongst the most disabling health conditions (Murray, C. J., Vos et al. 2012) and affects about 21 million people worldwide (Vos, Allen et al. 2016). People with schizophrenia have a life expectancy that is 15 years shorter than that of the general population, thought to be a result of increased rates of comorbid physical illness, increased smoking and drug use, reduced health-seeking behaviour as well as increased rates of suicide (Hjorthøj, Stürup et al. 2017, Pillinger, D’Ambrosio et al. 2019). Patients with schizophrenia experience positive, negative and cognitive symptoms affecting many aspects of their day-to-day functioning (McCutcheon, Robert A., Marques et al. 2020). Positive symptoms comprise hallucinations, delusions and thought disorder. Negative and cognitive symptoms include anhedonia, associality, avolition, alogia, blunted affect, inattention, poor executive functioning and working memory problems (Abi-Dargham 2014).

Subcortical dopamine dysfunction is thought to be a final common pathway to psychosis in many patients (Howes, Oliver D., Murray 2014). Supporting this, in vivo imaging studies have found large effect size increases in pre-synaptic dopamine synthesis and release in the striatum which are suspected to drive positive symptoms (McCutcheon, Robert, Beck, Jauhar, and Howes 2018a, Brugger, Angelescu et al. 2020a). Conversely, hypodopaminergia in the cerebral cortex has been linked to negative and cognitive symptoms (Slifstein, Van De Giessen et al. 2015). There is also evidence for the involvement of other neurotransmitter systems, in particular the serotonergic, cholinergic, and glutamatergic systems in the pathophysiology of schizophrenia (Kaar, Natesan et al. 2020, Selvaraj, Arnone et al. 2014).

Clinicians have a choice of over twenty licensed drug treatments to prescribe in schizophrenia (Christian, Saavedra et al. 2012, National Institute for Health and Care Excellence, (UK) ). Nevertheless, current treatment is inadequate for a number of reasons. Firstly, current antipsychotics predominantly target positive symptoms, and do little for negative and cognitive symptoms (Leucht, Cipriani et al. 2013a). Secondly, antipsychotics are ineffective for many patients (Demjaha, Lappin et al. 2017). The majority of patients with schizophrenia started on medication will experience at least one relapse over the subsequent five years (Robinson, Woerner et al. 1999), and between a quarter and a third have treatment resistance (Demjaha, Lappin et al. 2017, Lally, Ajnakina et al. 2016). Finally, current drugs result in a range of distressing and sometimes disabling side effects (Kaar, Natesan et al. 2020) including extrapyramidal side effects, and metabolic side effects such as weight gain, hyperlipidaemia and type 2 diabetes, which may also contribute to lower life expectancy (Patel, Cherian et al. 2014, Pillinger, McCutcheon et al. 2020a).

Tailoring antipsychotic treatment to an individual is a key component of the long-term management of schizophrenia. The efficacy and tolerability of treatment in an individual both affect the likelihood of a patient continuing treatment and thus determine response and risk of relapse (Taylor, Barnes et al. 2018, Barnes, Drake et al. 2020). Adverse effects are a common reason for treatment discontinuation, particularly when patients do not see a benefit in their symptoms either (Taylor, Barnes et al. 2018).

Thus there is a need for new treatment options with improved efficacy and better tolerability, which are also effective for negative and cognitive symptoms. In recent years there have been a number of new treatments licensed, and several more are in late phase development. The purpose of this narrative review is to consider new additions to the available treatments for schizophrenia since 2015 as well as emerging medicines on the horizon. We aim to provide an update to help clinicians and researchers appraise where these new and emerging additions fit within the therapeutic arsenal. To this end, we review the clinically relevant pharmacology, clinical trial data and side-effect profile of these drugs and consider how they compare to established antipsychotics. We chose eight widely used antipsychotics as our reference group: haloperidol, chlorpromazine, amisulpiride, risperidone, olanzapine, quetiapine, aripiprazole and clozapine. We focus on highlighting the differences and potentially advantageous aspects of the new drugs relative to established antipsychotics.

**2. Method**

We aimed to review recent developments in the drug treatment for schizophrenia. Thus, we restricted the compounds we considered to agents that have either been approved by the United States Food and Drug administration and/or the European Medicines Agency since the beginning of 2015, or drugs in development for schizophrenia listed on clinicaltrials.gov with at least one phase II clinical trial published since the beginning of 2015.This identified the following compounds: cariprazine, brexpiprazole, lumateperone (or ITI-007), pimavanserin (or ACP-103), roluperidone (or MIN-101), ulotaront (or SEP-363856), xanomeline, Lu AF35700, BI 425809, BI 409306, brilaroxazine (or RP5063), F17464 and MK-8189. From May - October 2021 we then conducted a series of targeted literature searches in PubMed and clinicaltrials.gov for ‘schizophrenia’ paired with these psychopharmacological agents to identify published studies. Reference lists in publications identified by these searches were also checked to obtain any additional data sources. The websites of drug companies developing these medications were searched for press releases. Patent information was found by searching for the compound name in Google Scholar and including patents in the results. We selected phase II and phase III clinical trials assessing the efficacy and tolerability of these medications. We excluded trials evaluating patients with mental disorders other than schizophrenia. We extracted information on the pharmacology of each drug, reviewed all the clinical trial data and summarised the incidences of side-effects and adverse events. The evidence for each drug was evaluated according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework (Siemieniuk, Guyatt 2019) and an overall assessment of the quality of evidence was made.

**3. Cariprazine**

3.1 Pharmacology

Cariprazine is a partial agonist at dopamine D2 and D3 receptors, with an almost seven-fold greater affinity for D3 relative to D2 receptors (Ki= 0.085nM and 0.59nM respectively, see Table 1 and Figure 2 (Corponi, Serretti et al. 2017, Citrome 2013)). This distinguishes cariprazine from the majority of other antipsychotics, which have low or negligible D3 receptor affinity (see Figures 1 and 3). Of note, blonanserin also has a high affinity for D3 (Ki=0.494nM), although this is still lower than cariprizine’s, and blonanserin has a higher affinity for D2 than cariprazine (Ki=0.142 nM) (Tenjin, Miyamoto et al. 2013). It has been proposed that cariprazine’s high affinity for D3 receptors relative to D2 could be effective for negative and cognitive symptoms (Krause, Zhu et al. 2018). Cariprazine has similar intrinsic agonist activity at the D2 receptor compared to aripiprazole, though higher intrinsic agonist activity at D3 (Tadori, Forbes et al. 2011, Kiss, Horváth et al. 2010).

Cariprazine is also a partial agonist at 5-HT1A receptors (Ki=3.0nM), although this is one-fifth affinity of its affinity for D2 receptors (Citrome 2013), and is an antagonist at 5-HT2B receptors with similar affinity (Ki=0.58nM) to its affinity for D2 receptors (Kiss, Horvath et al. 2010). It is also an antagonist at 5HT2A and H1 receptors, albeit with affinities for these receptors that are between 1/10 and 1/100th that of its affinity for D2 (Citrome 2013). Cariprazine has very low affinity (less than 1/100 of its affinity for D2) for 5HT2C and α1 receptors, meaning it is likely to have negligible occupancy of these at clinical doses (Citrome 2013).

Following administration of a single dose of cariprazine, peak plasma concentration is reached within 3-6 hours (Garnock-Jones 2017). Cariprazine is metabolised hepatically by cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2D6 (CYP2D6) enzymes to two equipotent metabolites, desmethyl cariprazine and didesmethyl cariprazine (Reyad, Mishriky 2019). After repeated doses, steady state is reached between weeks 1 and 2 for cariprazine and desethyl cariprazine and between weeks 4 and 8 for didesmethyl cariprazine (Garnock-Jones 2017). The elimination half-life of cariprazine and desmethyl cariprazine is 2-5 days and of didesmethyl cariprazine is 2-3 weeks (Garnock-Jones 2017, Reyad, Mishriky 2019).

**Box 1: Pharmacology definitions**

An **agonist** is a chemical that binds to and activates a receptor to result in a biological response. A **partial agonist** binds to and activates a receptor, but is not able to elicit the maximum possible response produced by a full agonist. In contrast, an **antagonist** blocks the action of the agonist, while an **inverse agonist** causes a pharmacological action opposite to that of the agonist. **Affinity** refers to the strength of the binding of the ligand to the receptor, or the likelihood that the ligand will bind to the receptor when it is in close proximity.

(Atack, Lavreysen 2010, Jackson 2010, Christopoulos, Stewart et al. 2010, Stewart, Sexton et al. 2010, Slifstein 2010).

[Table 1 to appear here]

[Figure 1 to appear here]

[Figure 2 to appear here]

3.2 Clinical efficacy

There have been four placebo-controlled randomised controlled trials (RCTs) of cariprazine to date in 2172 patients in total (Table 2). All tested use of cariprazine or placebo for a treatment period of 6 weeks in patients experiencing an acute relapse of schizophrenia.

Three of these studies (Durgam et al 2015, Kane et al 2015 and Durgam et al 2014) found a statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) with cariprazine compared to placebo (Durgam, Cutler et al. 2015, Kane, Zukin et al. 2015, Durgam, Starace et al. 2014).

The Durgam et al 2016 study did not find a significant difference in outcome between low and high dose cariprazine groups and the placebo group after correction for multiple comparisons. However, without correction for multiple comparisons the low dose cariprazine group showed significantly greater reduction in PANSS total and PANSS negative scores compared to placebo (Durgam, Litman et al. 2016).

Meta-analyses estimate the mean difference in change from baseline in PANSS total score for patients taking cariprazine compared to placebo is between -6.23 and -9.71 following 6 weeks of treatment ((Cooper, Mishriky et al. 2020, Zhao, Qin et al. 2018, Corponi, Serretti et al. 2017), an improvement of similar magnitude to that seen with other antipsychotics on meta-analysis (Mizuno, McCutcheon et al. 2020, Leucht, Cipriani et al. 2013b). This amelioration in symptoms is clinically significant, with more patients on cariprazine shifting to an improved category on the Clinical Global Impression (CGI) scale after treatment compared to those on placebo (Durgam, Earley et al. 2017).

Two RCTs included an arm with another antipsychotic as an active comparator. In the Durgam et al 2014 study, all cariprazine groups (1.5-4.5mg) and the risperidone 4mg group showed a significant improvement in PANSS score over placebo, with the cariprazine groups resulting in a less marked mean change in PANSS compared to risperidone (Durgam, Starace et al. 2014). In the Durgam et al 2015 study, cariprazine 3mg, 6mg and aripiprazole 10mg were all superior to placebo with a statistically significant improvement in PANSS. The cariprazine 6mg group had a numerically greater change in PANSS compared to aripiprazole 10mg, though this difference was not tested for statistical significance (Durgam, Cutler et al. 2015).

One active controlled trial assessed the effect of cariprazine on negative symptoms. Nemeth et al randomised 461 patients with long-term stable schizophrenia and predominant negative symptoms to receive cariprazine 4mg or risperidone 4mg for 26 weeks. The cariprazine group had a statistically significant greater improvement in PANSS-factor score for negative symptoms compared to the risperidone group (mean difference -1.46, p 0.002) (Németh, Laszlovszky et al. 2017). The low absolute difference (-1.46) in PANSS-factor score for negative symptoms does raise the question of whether this is a clinically meaningful difference. Nevertheless, on the basis of this trial, the European Medicines Agency has included an indication of the efficacy of cariprazine for treatment of predominantly negative symptoms of schizophrenia on its license (European Medicines Agency ). Moreover, two observational studies of open label cariprazine have found a clinically significant improvement in negative symptoms in patients treated with cariprazine in real-life settings (Smulevich, Ivanov et al. 2020, Rancans, Dombi et al. 2021). Nevertheless, there is a need for further controlled trials of the effect of cariprazine on negative symptoms as there has been only one randomised controlled trial specifically investigating this question to date. Due to the complexity of negative symptoms and their assessment, it is also important to note the limitations of PANSS and other scales in evaluating negative symptoms in clinical trials and the need for better instruments (Blanchard 2006, Kirkpatrick 2006, Hopkins 2018).

Corponi et al carried out a network meta-analysis of the efficacy of cariprazine on overall symptoms, positive and negative symptoms and quality of life, extracting the results from four randomised controlled trials of cariprazine and comparing them with those reported for other antipsychotics in previous meta-analyses (Corponi, Serretti et al. 2017). Cariprazine was ranked 14th out of 16 antipsychotics for overall efficacy, 7th out of 10 for effect on positive symptoms and 5th out of 11 for effect on negative symptoms, ranking higher than aripiprazole in this last domain. As part of this meta-analysis, a meta-regression was additionally carried out to identify the impact of clinical and demographic variables on response to cariprazine. This found that a high baseline PANSS score, shorter duration of disease and younger age were associated with greater response to cariprazine (Corponi, Serretti et al. 2017), in line with findings for other antipsychotics (Howes, Oliver D., Whitehurst et al. 2021).

There has been one long-term study looking at the efficacy of cariprazine in preventing relapse. 765 patients were enrolled to receive open-label cariprazine (3, 6 or 9mg) for 20 weeks (Durgam, Earley et al. 2016). 200 patients who completed this treatment and were then eligible to continue in the next phase of the study were then randomised to either continue cariprazine or receive placebo in the double-blind treatment phase of up to 72 weeks. For those continuing on cariprazine, mean time from baseline to first symptom relapse was 224 days compared to 92 days for the placebo group (Durgam, Earley et al. 2016) .

Two studies investigating cariprazine use in children and adolescents are due to read out in the next few years.

[Table 2 to appear here]

3.3 Side effect profile

In the pooled data from 8 short- and long-term clinical trials of cariprazine, the most commonly reported adverse events were akathisia (14.6%), insomnia (14%) and headache (12.1%) (Barabássy, Sebe et al. 2021). The incidence of extrapyramidal disorder was 7.0% (Barabássy, Sebe et al. 2021). Sedation and somnolence affected 3.7% and 3.1% of subjects respectively (Barabássy, Sebe et al. 2021). Overall, cariprazine has been characterised as a predominantly activating antipsychotic, where rates of akathisia and restlessness are higher than rates of sedation or somnolence (Citrome 2017). Nevertheless, akathisia is generally of mild to moderate severity and >93% of study participants experiencing akathisia were able to continue cariprazine (Barabássy, Sebe et al. 2021). The majority of cases of akathisia also responded to anti-extrapyramidal symptom medication or drug down-titration (Barabássy, Sebe et al. 2021).

In terms of metabolic effects, cariprazine has been associated with a small increase in weight (mean increase of 1.58 kg over 48 weeks) (Nasrallah, Earley et al. 2017). Levels of total cholesterol, high-density lipoprotein (HDL) and fasting triglycerides decreased from baseline following initiation of cariprazine (Barabássy, Sebe et al. 2021). Increases in fasting glucose were small and same as placebo (mean change of 0.3 mmol/L) (Barabássy, Sebe et al. 2021). Cariprazine stands out as the only antipsychotic associated with a significant reduction in low-density lipoprotein (LDL) cholesterol in short-term placebo controlled trials (Pillinger, McCutcheon et al. 2020a). Cariprazine is not associated with hyperprolactinaemia (Barabássy, Sebe et al. 2021, Earley, Durgam et al. 2017, Lao, He et al. 2016). There are very few incidences of QT prolongation with cariprazine, with 0.4% of patients from the pooled tolerability data reporting QTc >500 msec (Barabássy, Sebe et al. 2021). Szatmári et al extracted data from two clinical studies including 49 adolescents and 17 elderly patients and found that cariprazine was generally safe and well-tolerated in the these populations and that frequencies of adverse events were similar to the adult population (Szatmári, Barabássy et al. 2020).

With regard to serious adverse events (SAEs), Earley et al observed in their pooled analysis of safety and tolerability data that the most commonly reported SAE was worsening of schizophrenia (2.8% of cariprazine group versus 5% of placebo groups) (Earley, Durgam et al. 2017). In these data, two deaths occurred. Both were in the cariprazine 6mg group; one a suicide and the other classified as an ischaemic stroke/myocardial infarction. Neither death was considered related to treatment. Overall, suicidal ideation and suicidality treatment-emergent adverse events were similar for cariprazine and placebo groups (3.6 vs 4.7% and 0.4% vs 0.2% respectively) (Earley, Durgam et al. 2017). The more recent pooled analysis by Barabássy et al found rates of SAEs were lower among the cariprazine group compared to placebo (2.7% vs 3.1%) but the specific causes of SAEs were not defined further (Barabássy, Sebe et al. 2021). Barabássy et al found that suicidality was more common in the cariprazine group over placebo, though <1% overall (0.9% vs 0.1%) (Barabássy, Sebe et al. 2021).

3.4 Summary

Cariprazine has been shown to result in clinically significant improvement in patients experiencing an acute relapse of schizophrenia, though on a network meta-analysis uses indirect comparisons its ranking relative to other antipsychotics in terms of overall efficacy was relatively low. One maintenance study showed its efficacy in delaying time to relapse over placebo, but further long-term studies are needed to investigate this. There is some evidence that cariprazine is particularly effective in treating negative symptoms which may be linked to its high affinity for D3 receptors, though further testing in this group is warranted. Cariprazine may also be of benefit to patients with irregular medication compliance, due to the long half-life of its active metabolite didesmethyl cariprazine. Cariprazine is an activating antipsychotic with relatively higher rates of akathisia and restlessness than other newer antipsychotics, and is thus recommended for morning dosing. It has minimal metabolic side effects and would be a good choice for patients with metabolic risk factors.

[Figure 3 to appear here]

**4. Brexpiprazole**

4.1 Pharmacology

Brexpiprazole is a dopamine partial agonist belonging to the same class as aripiprazole and cariprazine (Demyttenaere, Detraux et al. 2019). It has a greater affinity for D2 receptors (Ki=0.3nM) and lower affinity for D3 receptors (Ki=1.1nM) compared to both aripiprazole and cariprazine (Roth, Lopez ). Brexpiprazole also has a greater affinity for D1 and D4 receptors (Ki=164 and 6.3 nM respectively) than aripiprazole as shown in Table 1 and Figure 1. There are no data for the affinity of cariprazine for these receptors, precluding comparison.

The intrinsic agonist activity of aripiprazole at D2 is reported at 25-90% of that of dopamine, depending on assay-specific factors including receptor density (Burris, Molski et al. 2002). In one assay directly comparing the two antipsychotics, brexpiprazole demonstrated intrinsic agonist activity at D2 of 43% of that of dopamine, whereas for aripiprazole this was 61% (Maeda, Sugino et al. 2014). Thus, although it has greater affinity for D2, brexpiprazole has less intrinsic agonist activity at this receptor compared to aripiprazole.

Brexpiprazole is a partial agonist at 5HT1A receptors and antagonist at 5-HT2A and α1 receptors (Demyttenaere, Detraux et al. 2019, Kishi, Ikuta et al. 2020). With the exception of 5HT2C, brexpiprazole binds to serotonin, alpha adrenergic and histamine receptors with greater affinity than aripiprazole and cariprazine (notwithstanding the lack of data for cariprazine’s affinity for α1 and α2 receptors, see Table 1 and Figures 1 and 3) (Roth, Lopez , Stahl 2017, Nerkar, Bhise ).

Peak plasma concentration of brexpiprazole is attained 4 hours after a single dose administration. Steady-state concentrations after repeated dosing are reached in 10-12 days (Mauri, Paletta et al. 2018). Like cariprazine, brexpiprazole is metabolised by CYP3A4 and CYP2D6 enzymes, though its major metabolite, DM-3411, does not contribute to its therapeutic effects. The elimination half-life of brexpiprazole is 3-4 days (Mauri, Paletta et al. 2018).

4.2 Clinical efficacy

There have been five short-term randomised placebo-controlled trials of brexpiprazole to date, with a total of 2683 patients (Table 3). All investigated brexpiprazole’s efficacy in patients experiencing an acute relapse of schizophrenia for a treatment period of six weeks, with two studies also including a treatment arm with an alternative antipsychotic (quetiapine or aripiprazole) as an active control. The primary outcome measure in all five short-term studies was change in PANSS score from baseline.

Three of the studies found that the brexpiprazole group had a greater reduction in PANSS score compared to placebo, though this difference only reached statistical significance for specific brexpiprazole dose groups in each trial (2mg in the study by Ishigooka et al (Ishigooka, Iwashita et al. 2018), 2mg and 4mg in the ‘Vector’ study (Correll, Skuban et al. 2015), and 4mg in the ‘Beacon’ study (Kane, Skuban et al. 2015)). The other doses of brexpiprazole tested in these studies did lead to a numerically greater reduction in PANSS score over placebo but did not reach statistical significance.

A further study by Correll et al did not find a significant difference in change in PANSS between the brexpiprazole treatment groups and the placebo group, but the aripiprazole active control group also failed to separate from placebo (Correll, Skuban et al. 2016). In the ‘Lighthouse’ study (NCT01810380), the brexpiprazole group failed to separate from the placebo group but also had a statistically significant poorer outcome at the end of the study compared to the quetiapine group (Marder, Hakala et al. 2017). There was notably a high placebo response in the Lighthouse study, and additionally further analysis found that functional unblinding of patients experiencing typical side effects of quetiapine may have been a confounding factor resulting in its better performance over brexpiprazole (Marder, Eriksson et al. 2020).

When the data of the Vector, Beacon and Lighthouse studies were analysed together, brexpiprazole 2-4mg was found to result in a statistically significant improvement in PANSS score over placebo (treatment difference -5.8, p<0.0001) (Marder, Hakala et al. 2017). Post-hoc analysis of these three studies also showed that the brexpiprazole group had a greater mean reduction in PANSS particularly among the more severely ill patients (Meade, Shi et al. 2020).

Additional work has further investigated the efficacy of brexpiprazole relative to other antipsychotics. Citrome et al 2016 performed a randomised open-label study testing use of brexpiprazole or aripiprazole over 6 weeks, and did not find a significant difference in reduction in PANSS score between either antipsychotic (Citrome, Ota et al. 2016). Moreover, a recent network meta-analysis of thirty-two oral antipsychotics ranked brexpiprazole 31st (out of 32 drugs) for overall change in symptoms, 21st (out of 21) for effect on positive symptoms and 18th (out of 21) for effect on negative symptoms (Huhn, Nikolakopoulou et al. 2019). Brexpiprazole performed relatively better with respect to effect on social functioning and was ranked 6th out of the 13 antipsychotics where this was measured (Huhn, Nikolakopoulou et al. 2019).

The ‘Equator’ maintenance study investigating treatment over 52 weeks concluded that brexpiprazole significantly delayed time to relapse relative to placebo (Fleischhacker, Hobart et al. 2017). Two further open label extension studies found that brexiprazole 1-4mg was associated with mean reductions in PANSS score of -12.2 and -6.8 respectively (Forbes, Hobart et al. 2018, Hakala, Gislum et al. 2018).

Table 3 shows five studies currently in progress for brexpiprazole which are due to complete in the next few years. They are investigating brexpiprazole use in particular patient groups, including adolescents and comorbid substance users, as well as further exploring the incidence of adverse events.

[Table 3 to appear here]

4.3 Side-effect profile

In the 52-week open label study of 1072 patients by Forbes et al, the most common treatment-emergent adverse events were insomnia (8.6%), weight gain (7.8%), headache (6.4%) and agitation (5.4%) (Forbes, Hobart et al. 2018). The second open label study with a smaller sample size of 210 patients by Hakala et al also found similar rates of these adverse events (Hakala, Gislum et al. 2018). Brexpiprazole has almost half the incidence of akathisia compared to aripiprazole (5.5% compared to 10.0%) (Forbes, Hobart et al. 2018), and, furthermore, a lower incidence than cariprazine (Demyttenaere, Detraux et al. 2019).

A network meta-analysis of the metabolic effects of antipsychotics determined brexpiprazole, alongside aripiprazole, to be associated with the best metabolic outcomes and one of the agents of choice for patients with an increased risk of developing metabolic complications (Pillinger, McCutcheon et al. 2020b). Brexpiprazole is associated with a small increase in weight (mean increase 2.1kg over 52 weeks) (Forbes, Hobart et al. 2018). Nevertheless, there is no associated effect on glucose, total cholesterol, LDL, triglycerides or QTc interval for brexpiprazole compared to placebo (Huhn, Nikolakopoulou et al. 2019, Pillinger, McCutcheon et al. 2020b). Brexpiprazole is not associated with sustained hyperprolactinaemia (Ivkovic, Lindsten et al. 2019).

There were six deaths in the safety and tolerability data for 2315 patients on brexpiprazole pooled by Kane et al, but none of these were considered related to the medication (Kane, Skuban et al. 2016, Forbes, Hobart et al. 2018). In short term studies, rates of treatment-emergent adverse events (TEAEs) related to suicidality were the same for brexpiprazole and placebo groups (0.2%), and in long term studies, 0.8% of patients on brexpiprazole reported a TEAE related to suicidality (Kane, Skuban et al. 2016).

4.4 Summary

Brexpiprazole has had mixed results with respect to its clinical efficacy in clinical trials to date, with some doses not separating from placebo in some trials. However, in one of these trials the comparator antipsychotic also failed to separate, suggesting the trial may have been sub-optimal to test efficacy. Brexpiprazole has a relatively favourable side effect profile; it is less activating than aripiprazole, and has minimal metabolic effects. Studies in progress will provide further information about its efficacy, long-term tolerability and role in treating specific patient sub-groups.

**5. Brilaroxazine (RP5063)**

5.1 Pharmacology

Brilaroxazine (RP5063) has a chemical structure that is similar to aripiprazole, and acts as a high-affinity partial agonist on D2, D3 and D4 receptors (Ki= 0.37nM, 3.7nM and 6.0nM respectively), and on serotonin 5-HT1A and 5-HT2A receptors (Ki= 1.5nM, 2.5nM respectively) (Cantillon, Prakash et al. 2017). Brilaroxazine also has antagonistic activity on serotonin 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 receptors (Ki= 0.19nM, 39nM, 51nM and 2.7nM respectively) and has moderate affinity for the serotonin transporter (Ki=107nM) (Cantillon, Prakash et al. 2017).

Brilaroxazine has a half-life of over 40 hours allowing once-daily dosing, with steady-state reached after 8 days of administration (Cantillon, Prakash et al. 2017).

5.2 Clinical Efficacy

A phase II randomised controlled trial of brilaroxazine in acute relapse of schizophrenia or schizoaffective disorder found that the brilaroxazine 15mg and 50mg groups showed statistically significant reductions in PANSS total score compared to the placebo group (Table 4) (Cantillon, Prakash et al. 2017). The brilaroxazine 30mg arm did not show statistically significant difference relative to placebo, which the authors reported may have been due to a larger number of drop-outs in this group for reasons not related to medication. The active control group, aripiprazole 15mg, also failed to separate from placebo, though the authors commented that this group had solely been included for sensitivity analysis and not as a comparator (Cantillon, Prakash et al. 2017). PANSS subscale scores showed greater brilaroxazine improvement versus placebo in PANSS negative and prosocial symptoms than positive symptoms (Cantillon, Prakash et al. 2017). There are currently no further clinical trials of brilaroxazine registered on clinicaltrials.gov, though the authors of the published phase II study report that they intend to initiate two further phase III trials (Cantillon, Bhat 2018).

[Table 4 to appear here]

5.3 Side effect profile

In NCT0149008, commonly reported treatment emergent adverse events (occurring in ≥ 2% of any brilaroxazine group and not reported for placebo) included extrapyramidal symptoms, akathisia, and raised liver enzymes, though >95% of these were mild or moderate in severity (Cantillon, Prakash et al. 2017). Among 170 subjects receiving brilaroxazine, there were 4 serious treatment emergent adverse events (all of which were elevated liver enzymes). Additionally in the brilaroxazine group, 1 subject had a grand mal seizure and there was 1 case of epileptiform discharges on EEG (Cantillon, Prakash et al. 2017). There were no significant changes to BMI, serum glucose, prolactin or ECG parameters in the brilaroxazine group (Cantillon, Prakash et al. 2017). Maintenance studies are needed to assess the long-term efficacy and tolerability of brilaroxazine.

5.4 Summary

Brilaroxazine is a partial agonist on D2, D3 and D4 receptors as well as serotonin 5HT1A and 5-HT2A receptors with a long half-life which may be helpful for patients with intermittent compliance. One phase II study found that brilaroxazine 15mg and 50mg groups showed statistically significant improvement in PANSS score relative to placebo, though the 30mg group did not. Brilaroxazine is associated with a low incidence of extrapyramidal symptoms and no metabolic effects, though further long-term studies are needed.

**6. Lumateperone (ITI-007)**

6.1 Pharmacology

Lumateperone (ITI-007) was selected from a series of compounds tested for their suitability as potential new antipsychotics because of its very high affinity for serotonin 5-HT2A receptors and additional interactions with dopamine receptors and serotonin transporters (Davis, Robert E., Correll 2016).

Lumateperone is a 5-HT2A antagonist, with a 60-fold higher affinity for 5-HT2A receptors compared to D2 receptors (Ki values of 0.54nM and 32 nM respectively; see Figure 2) (Snyder, Vanover et al. 2015). At clinical antipsychotic doses, lumateperone is therefore likely to result in near total blockade of 5-HT2A receptors (Davis, Robert E., Correll 2016).

It has been suggested that lumateperone could act as an agonist at presynaptic dopamine D2 autoreceptors to reduce dopamine synthesis whilst also acting as an antagonist at postsynaptic dopamine D2 receptors. Supporting this hypothesis, Snyder et al found that lumateperone demonstrates postsynaptic D2 antagonism and presynaptic D2 partial agonism in the striatum of mice (Snyder, Vanover et al. 2015). In contrast, Zhang and Hendrick carried out agonist and antagonist assays of lumateperone and other antipsychotics in Chinese Hamster Ovary (CHO) cells expressing recombinant human D2L and D2S receptors (Zhang, Hendrick 2018), and found that lumateperone demonstrated full antagonism at both D2L and D2S, with no demonstrable agonism at either receptor. In vivo, D2L receptors are found in postsynaptic dopamine responsive cells, and the D2S receptor (a splice variant of D2L hypothesised to be the autoreceptor) is most abundant on presynaptic dopamine cells (Usiello, Baik et al. 2000). These data thus question whether lumateperone does show presynaptic D2 agonism, although the authors acknowledged that the G-proteins found in CHO cells do not replicate those found in human presynaptic cells (Zhang, Hendrick 2018). Notwithstanding this, further work is needed to test if lumateperone does show agonism at presynaptic D2 receptors.

N-methyl-D-aspartate (NMDA) receptor hypofunction is thought to contribute to the pathophysiology of schizophrenia (Kokkinou, Irvine et al. 2020a). Lumateperone has been found to increase NMDA receptor activity in mesolimbic regions by increasing the phosphorylation of the GluN2B subunit (Corponi, Fabbri et al. 2019, Snyder, Vanover et al. 2015). Thus, in addition to its actions on the dopamine system, lumateperone could help address glutamatergic dysfunction in the disorder (McCutcheon, Robert A., Krystal et al. 2020). Additionally, lumateperone inhibits serotonin reuptake via inhibition of serotonin transporters (with a moderate affinity, Ki=62 nM), which could also contribute to its therapeutic action (Davis, Robert E., Correll 2016).

Lumateperone binds to a number of other receptors to a lesser degree. It has moderate affinity for α1, α2 and 5-HT2C receptors (Ki=73, <100 and 173 nM respectively) and low affinity for M3 and H1 receptors (Ki>100nM and >1000nM respectively, see figures 1 and 3). Whether lumateperone has agonist or antagonist activity at these receptors is not clear to date (Meyer 2020, Snyder, Vanover et al. 2015, Blair 2020).

A PET study of patients with schizophrenia receiving lumateperone 60mg daily found that the mean peak dorsal striatal D2 receptor occupancy of lumateperone was 39%, a lower receptor occupancy level than most currently licensed antipsychotic drugs at their efficacious doses (Vanover, Kimberly E., Davis et al. 2019).

Lumateperone is available as oral capsules of the compound lumateperone tosylate. Lumateperone tosylate 60mg contains 42mg of the active moiety lumateperone (U.S. Food and Drug Administration 2019). Following oral administration, lumateperone is rapidly absorbed and reaches peak plasma concentration in 3-4 hours. The drug is metabolised by CYP3A4 of the cytochrome P450 system (Davis, Robert E., Correll 2016). Lumateperone has a half-life of 13 hours and lumateperone’s metabolites, IC200161 and IC200131, have half-lives of 20 and 21 hours respectively (Davis, Robert E., Correll 2016). The metabolites IC200161 and IC200131 are both active and have a similar pharmacologic profile to lumateperone (Davis, Robert E., Correll 2016). ICI200131 can also be metabolically transformed by CYP3A4 back to lumateperone, resulting in sustained plasma lumateperone levels (Davis, Robert E., Correll 2016).

6.2 Clinical efficacy

Lumateperone was first approved in December 2019 in the USA for the treatment of adults with schizophrenia (Blair 2020). There have been three randomised controlled trials of lumateperone to date in 1481 patients in total (Table 5). All investigated lumateperone’s use in patients with an acute relapse of schizophrenia over a treatment period of 4-6 weeks.

Two of the RCTs (ITI-007-005 and ITI-007-301) had positive findings, though in both trials only the group receiving the 60mg dose of lumateperone tosylate showed a significantly greater improvement in PANSS score relative to the placebo group. The lumateperone tosylate 120mg group in ITI-007-005 and lumateperone tosylate 40mg group in ITI-007-301 both failed to separate from placebo (Lieberman, Davis et al. 2016, Correll, Davis et al. 2020) .

The authors of the ITI-007-005 study suggested the lack of efficacy for total symptoms with lumateperone tosylate 120mg may have been the result of increased sedation masking signs of clinical improvement (Lieberman, Davis et al. 2016). However, in this study there was also no significant change relative to placebo in the PANSS positive subscale for the lumateperone tosylate 120mg group. As change in positive symptoms may be expected to be less sensitive to sedation, this could suggest that other factors also contributed to the lack of significant differences.

In study ITI-007-302, neither lumateperone tosylate 20mg nor 60mg separated from placebo, while the active control (risperidone 4mg) did (Vanover, Kimberly, Dmitrienko et al. 2018). Nevertheless, a high placebo response rate was observed in this trial, which could have reduced the power of the study to detect effects in the active arms.

In further analysis, study ITI-007-005 found that lumateperone tosylate 60mg significantly reduced scores on the PANSS-derived prosocial factor, which assessed difficulties with social functioning (Lieberman, Davis et al. 2016). Similarly, the results of study ITI-007-301 indicated that patients taking lumateperone tosylate 60mg demonstrated improved social functioning compared to placebo (Correll, Davis et al. 2020). With regards to depressive symptoms, an a priori defined subgroup analysis in study ITI-007-005 found that lumateperone tosylate 60mg significantly reduced the Calgary Depression Scale for Schizophrenia in the 7 patients in this arm with symptoms of depression (Lieberman, Davis et al. 2016). This fits with an expected antidepressant effect due to its inhibition of serotonin reuptake and could suggest a role for lumateperone in schizophrenia with co-morbid depression, although this requires further testing in a much larger study.

The results of two additional open label studies investigating the pharmacokinetics and tolerability of lumateperone long acting injection and of oral lumateperone in adolescents are awaited.

[Table 5 to appear here]

6.3 Side effect profile

In a pooled analysis of short-term placebo controlled trials (n=818), the most common adverse events in patients receiving lumateperone tosylate 60mg were sedation (24%), nausea (9%), dry mouth (6%), dizziness (5%), increased creatine phosphokinase (4%), fatigue (3%), vomiting (3%), increased hepatic transaminases (2%) and decreased appetite (2%). In these trials the incidence of extrapyramidal symptoms was 6.7% with lumateperone and 6.3% with placebo (U.S. Food and Drug Administration 2019). In the short-term studies, weight gain occurred in 2% of lumateperone groups compared to 3% of placebo (corresponding mean weight change of +1.6kg and +1.3kg) (Kane, Vanover et al. 2020). A more recent open-label tolerability study of 301 outpatients found the incidence of extrapyramidal symptoms to be 1.0%, lower than the aforementioned pooled analysis (Correll, Vanover et al. 2021).

There has been one longer term open-label safety study in 602 patients, which showed that lumateperone was well tolerated over 1 year (Satlin, A., Vanover et al. 2019). In the long-term study, lumateperone was associated with significant reductions from baseline in mean body weight, BMI and waist circumference (Satlin, Andrew, Durgam et al. 2020).

Like cariprazine and brexpiprazole, lumateperone has a favourable cardiovascular profile, with no QTc interval prolongation (Davis, Robert, Dmitrienko et al. 2018). In the 12 month open-label study, total cholesterol, LDL and prolactin levels decreased when patients were switched from their standard antipsychotic treatment to lumateperone (Satlin, A., Vanover et al. 2019). Post-hoc analysis of studies ITI-007-005, ITI-007-302 and ITI-007-303 showed that patients on lumateperone had reduced rates of metabolic syndrome at the end of both the short term and long term studies (Edwards, Satlin et al. 2021).

Two patients on lumateperone in the ITI-007-301 study experienced severe treatment emergent adverse events that led to them discontinuing treatment; one was orthostatic hypotension and the other convulsions (in a patient with pre-existing risk factors and a history of seizures) (Correll, Davis et al. 2020). There were no deaths in the RCTs in the lumateperone group and no increase in suicidal ideation or behaviour.

6.4 Summary

Lumateperone’s pharmacology is characterised by high-affinity 5HT2A antagonism, inhibition of serotonin transporters and relatively low striatal D2 receptor occupancy compared to other antipsychotics at therapeutic doses (McCutcheon, Robert A., Marques et al. 2020). Two of three RCTs investigating its efficacy have shown positive results in total symptoms over placebo, with some indication that it may also improve social functioning and depressive symptoms. Lumateperone appears to have a favourable tolerability profile, with rates of extrapyramidal symptoms similar to placebo and no significant metabolic side effects detected in short and long-term studies, though a quarter of patients in short-term studies experienced sedation. Further efficacy and safety trials are required, especially long-term studies, and there has yet to be a relapse prevention study.

**7. F17464**

7.1 Pharmacology

F17464 is a D3-antagonist and 5-HT1A partial agonist (Cosi, C., N’Guyen et al. 2017). Like cariprazine, F17464 has very high affinity for D3 receptors (Ki=0.17nM) and 5-HT1A receptors (Bitter, I., Groc et al. 2017, Cosi, C., N’Guyen et al. 2017). F17464 exhibits high affinity for D2 receptors (Ki=9.3nM) where it acts as a very weak partial agonist (Cosi, C., N’Guyen et al. 2017). A PET-scan study in healthy volunteers showed that F17464 has >80% D3 receptor occupancy with little (<20%) D2 receptor occupancy at 15 and 30mg (Slifstein, Abi-Dargham et al. 2020).

Evidence suggests there is restricted distribution of the D3 receptor in the brain and that it plays a role in limbic brain functions by modulating glutamatergic pathways (Sokoloff, Le Foll 2017). The D3 antagonism of F17464 could potentially improve cognition by addressing low dopamine tone in the prefrontal cortex, while partial agonism at 5-HT1A could also be associated with pro-cognitive effects (Bitter, I., Groc et al. 2017).

Maximum plasma concentration of F17464 is reached 0.5 – 4 hours after oral administration (Slifstein, Abi-Dargham et al. 2020). Steady-state is reached after 15 days (Bitter, Istvan, Lieberman et al. 2019). The PET study indicated that while the mean plasma half-life of F17464 is 1.32 hours, the drug remains detectable at D3 receptors 22 hours post-dose, making it suitable for twice-daily dosing (Slifstein, Abi-Dargham et al. 2020).

7.2 Clinical Efficacy

There has been one short-term phase II double blinded RCT of F17464 (Table 6), which found a statistically significant improvement in PANSS score for the F17464 20mg BD group over placebo (Bitter, Istvan, Lieberman et al. 2019). Secondary efficacy analyses also found a statistically significant effect of F17464 on PANSS positive score, but no difference in PANSS negative score or Marder negative factor (Bitter, Istvan, Lieberman et al. 2019). Nevertheless, the study population (acute relapse of schizophrenia) and short duration of the study meant the trial was unlikely to have adequately tested a potential effect on negative symptoms. Post-hoc analysis in this study using the Wallwork factors of the PANSS items did suggest a beneficial effect of F17464 on cognitive ability (Bitter, Istvan, Lieberman et al. 2019). Of note, the authors stated that 10 randomised patients had been excluded from the manuscript due to the breach of Good Clinical Practice standards by one study centre. There were also major protocol deviations for a further 19 subjects, whose data was analysed in the full analysis set, but not in the per protocol set (Bitter, Istvan, Lieberman et al. 2019).

[Table 6 to appear here]

7.3 Side effect profile

The most common treatment-emergent adverse events in NCT02151656 with higher incidence in F17464 than placebo were insomnia (10.4%), agitation (7.5%), hyperlipidaemia (7.5%) and akathisia (4.5%) (Bitter, Istvan, Lieberman et al. 2019). All serious adverse events in this study were lack of efficacy-related adverse events (14.9% on F17464 and 22.4% on placebo). 13 patients (19.4%) in the F17464 arm discontinued treatment, which was due to treatment inefficacy (11 patients), raised liver enzymes (1 patient) and suicidal ideation (1 patient) (Bitter, Istvan, Lieberman et al. 2019).

No patients taking F17464 reported extrapyramidal symptoms and F17464 did not lead to a clinically relevant change in ECG parameters. F17464 was associated with an increase in prolactin levels during the study and hyperprolactinaemia was more frequent and more marked in females (Bitter, Istvan, Lieberman et al. 2019).

7.4 Summary

F17464 is a high-affinity D3-antagonist and 5-HT1A partial agonist. One phase II study showed an improvement in PANSS score in the F17464 40mg group relative to placebo, with possible beneficial effect on cognition suggested from post-hoc analysis. F17464 is an activating antipsychotic with insomnia, agitation and akathisa some of the most common side effects. It is associated with hyperprolactinaemia.

**8. Lu AF35700**

8.1 Pharmacology

Lu AF35700 is an antagonist of D1, 5-HT2A and 5-HT6 receptors (Fellner 2017). A Positron Emission Tomography study has demonstrated Lu AF35700 has predominant D1 vs D2 dopamine receptor occupancy combined with high 5-HT6 receptor occupancy (NIH U.S. National Library of Medicine 2020a).

8.2 Clinical efficacy

There have been two clinical trials of Lu AF35700 in schizophrenia so far, both in treatment-resistance (Table 7). In both cases, treatment resistance was determined by a history of non-response to adequate prior antipsychotic treatment and failure of a prospective trial of either olanzapine or risperidone, after which non-responders were then randomised to either Lu AF35700 or to continue on the drug they were currently taking (olanzapine or risperidone). The ‘Anew’ study (NCT03230864) aimed to test Lu AF35700 in patients who had developed treatment resistance early or late in their illness. However, the Lu AF35700 10mg group was not significantly different from the risperidone/olanzapine group, though the study was likely under-powered as it achieved less than 50% of its patient recruitment targets (NIH U.S. National Library of Medicine 2020c). The ‘Daybreak’ study (NCT02717195) was much larger than the Anew study, enrolling over 1000 patients and recruiting over 200 patients to each double-blinded arm. It tested Lu AF35700 at doses of 10mg and 20mg. Whilst both groups showed reductions in PANSS total scores and improvements on other measures neither group performed significantly better than the active control (olanzapine/risperidone) group on the primary outcome of change in PANSS total score, or secondary outcomes (NIH U.S. National Library of Medicine 2019). Whilst these results show no significant advantage of Lu AF35700 over olanzapine/risperidone for treatment resistant schizophrenia, it remains unclear if it is efficacious in schizophrenia because there was no placebo control group.

[Table 7 to appear here]

8.3 Side effect profile

In the Daybreak study, the most common adverse events with Lu AF35700 were headache (4.6%-6.47% with Lu AF35700 10-20mg, compared to 3.4% with risperidone and 4.1% with olanzapine) and weight increase (3.4% with Lu AF35700 10mg, 8.2% with Lu AF35700 20mg vs 4.8% with olanzapine/risperidone) (NIH U.S. National Library of Medicine 2019) . The Anew study found a lower incidence of weight increase with Lu AF35700 10mg compared to continued olanzapine/risperidone (2.86% vs 9.09%) (NIH U.S. National Library of Medicine 2020c). No statistical testing was done to assess the statistical significance of these differences. There is no data regarding effects of Lu AF35700 on ECG parameters or prolactin.

The incidence of akathisia was <3% in both studies and was similar for Lu AF35700 and olanzapine/risperidone groups. In the Daybreak study, somnolence occurred in 1.3% of the Lu AF35700 10mg and 3.9% of Lu AF35700 20mg groups (compared to 1.8% with olanzapine/risperidone), while rates of somnolence were not reported in the Anew study (NIH U.S. National Library of Medicine 2019, NIH U.S. National Library of Medicine 2020c). There were no deaths among the patients taking Lu AF35700 (NIH U.S. National Library of Medicine 2019, NIH U.S. National Library of Medicine 2020c).

A maintenance study of open-label Lu AF35700 10-20mg/day over 57 weeks (NCT02892422) with results on clinicaltrials.gov (though not yet published) found that headache was the most common adverse event, affecting 8.2% of subjects. The incidence of other non-serious adverse events was not reported. 28 of 524 subjects (5.3%) experienced a serious adverse event; worsening of schizophrenia (21 subjects), suicide attempt (2), intentional overdose (2), myocardial infarction (1), pulmonary embolism (1), hip fracture (1), coma (1), parkinsonism (1), alcohol withdrawal (1), disinhibition (1) and insomnia (1). There were no fatalities (NIH U.S. National Library of Medicine 2020b).

8.4 Summary

Lu AF35700 is a D1, 5HT2A and 5HT2 receptor antagonist. There have been two clinical trials of Lu AF35700 in treatment resistance, neither of which found significant improvement with Lu AF35700 over olanzapine or risperidone active controls. Lu AF35700 was generally well-tolerated with the most common side effect reported being headache, and some evidence of an association with weight gain at the higher dose of 20mg.

**9. Pimavanserin (ACP-103)**

9.1 Pharmacology

Pimavanserin (ACP-103) is already licensed for psychosis in Parkinson’s disease in the United States of America, and is now being trialled for schizophrenia. Unlike the novel treatments discussed thus far, pimavanserin has minimal affinity for the dopamine receptor (Ki>1000nM, see Table 1). It has high affinity for the 5HT2A receptor (Ki=0.087nM, Table 1), where it is thought to act as an inverse agonist (ACADIA Pharmaceuticals Inc 2016). Interestingly, this high affinity for 5HT2A is similar to that of clozapine, which shows good efficacy in treating psychosis in Parkinson's disease (Hacksell, Burstein et al. 2014). Pimavanserin also has high affinity for 5HT2Creceptors (Ki=0.44nM) and appreciable, but much lower affinity for sigma-1 receptors (Ki=120nM), and negligible affinity ( Ki >1000nM) at 5-HT1A, 5-HT2B, histamine, muscarinic, and alpha receptors (ACADIA Pharmaceuticals Inc 2016) (see Figures 1 and 3), suggesting low risk of side-effects such as sedation and constipation due to actions at these receptors.

The half-life of pimavanserin is 57 hours with peak concentration occurring at 6 hours (Kitten, Hallowell et al. 2018), and the half-life of its chief metabolite is about 200 hours (Baltzersen, Meltzer et al. 2020). A positron emission tomography study demonstrated that 10mg of Pimavanserin was sufficient to occupy over 90% of brain 5HT2A receptors in healthy volunteers (Nordstrom, Mansson et al. 2008). Pimavanserin is metabolised by CYP 450 enzymes, and plasma pimavanserin levels decrease in combination with inducers such as rifampicin and increase in combination with inhibitors of this system (Kitten, Hallowell et al. 2018).

9.2 Clinical Efficacy

The initial studies of pimavanserin were in Parkinson’s disease psychosis, and the Food and Drug Administration approved its use in this condition in 2016, a decision upheld on review in 2018 (Meltzer, Mills et al. 2010). There was some controversy around the approval, since two trials failed to show a significant benefit relative to placebo (Hacksell, Burstein et al. 2014, Kitten, Hallowell et al. 2018, Webster 2018) and the study showing a significant benefit used a previously untested rating scale. Pimavanserin has subsequently been tested in schizophrenia, where it was well tolerated compared to placebo when added on to treatment as usual (Table 8) (Abbs, Bugarski-Kirola et al. 2020).

A press release reporting results from a phase-II clinical trial indicated no significant benefit of add-on treatment with pimavanserin on total PANSS score or clinical global impression (CGI), but a significant benefit on change in negative symptom scores relative to placebo (ACADIA Pharmaceuticals Inc 2019a). However, this statement reported an unadjusted p-value of 0.047, which is unlikely to survive correction for multiple statistical tests (ACADIA Pharmaceuticals Inc 2019a). A press release from a phase-III trial of pimavanserin as an add-on to usual antipsychotic treatment reported that there was no significant difference in total PANSS scores or CGI (ACADIA Pharmaceuticals Inc 2019b). There were significant benefits of add-on primavanserin in the PANSS negative symptoms subscale and PANSS Marder negative factor score (unadjusted p values 0.047 and 0.034 respectively), but it was not reported whether the results for these secondary outcomes would survive correction for multiple comparisons (ACADIA Pharmaceuticals Inc 2019b). Results are available on the National Library of Medicine Clinical Trials Database (ACADIA Pharmaceuticals Inc 2020a, ACADIA Pharmaceuticals Inc 2020b ) and data relating to safety and adherence has been published in abstracts (Abbs, Bugarski-Kirola et al. 2020, Bugarski-Kirola, Nunez et al. 2020) but a full peer-reviewed report is not yet available for either trial.

Three further studies in schizophrenia are ongoing and due to read out in the next three years. One study currently recruiting is a randomised placebo-controlled trial assessing the effect of adjunctive pimavanserin on negative symptoms (NCT04531982). The remaining two studies are open label; a year-long open-label study to assess tolerability (NCT03121586), and a study aiming to correlate treatment response to pimavanserin monotherapy and positron emission tomography measurements of 5HT2A occupancy (NCT03994965, Baltzersen, Meltzer et al. 2020).

[Table 8 to appear here]

9.3 Side effect profile

Pimavanserin did not worsen motor symptoms in Parkinson’s disease (Meltzer, Mills et al. 2010) and, similar to brexpiprazole and lumateperone, had low propensity to cause extrapyramidal side effects in schizophrenia (Bugarski-Kirola, Nunez et al. 2020). Pimavanserin is not associated with a rise in serum prolactin (Abbas, Roth 2008). There is a black box warning for increased risk of death when used in the elderly, similar to the recent warnings for other antipsychotics (Baltzersen, Meltzer et al. 2020). Pimavanserin increased QT by 7.2ms on average in a group of Parkinson’s patients over 40, and manufacturers suggest caution when co-prescribing with other drugs with QT-prolonging potential and avoiding use in patients with established QT prolongation (Markham 2016). In Parkinson’s disease trials, more patients suffered from the following adverse events in the pimavanserin group relative to the placebo group: nausea, peripheral oedema, confusion, hallucinations, constipation and gait disturbance, with a prevalence between 1 and 7% (Markham 2016, Cummings, Isaacson et al. 2014).

9.4 Summary

Pimavanserin stands out due to its combination of high affinity for 5HT2A receptors, where it is a partial agonist, and low affinity for D2 receptors. Trial data in Parkinson’s disease indicate it has a minimal propensity to cause extra pyramidal side effects. It has been studied as an adjunct to antipsychotics in patients with schizophrenia with no effect on total PANSS scores, but possible beneficial effects on negative symptoms, although these findings have not been subject to peer review.

**10. Roluperidone (MIN-101)**

10.1 Pharmacology

According to both a patent application and the main article for a recent phase-II trial, roluperidone (MIN-101) is a high affinity 5-HT2A antagonist (K­i= 8.19 nM), sigma 2 receptor antagonist (Ki = 7.53nM, and has some action as an alpha1-adrenergic antagonist (Luthringer, Pellegrini et al. 2013, Davidson, Saoud et al. 2017). However, detailed methods are not reported, including whether these binding assays were conducted on human brain tissue (see Table 1 and Figures 1 and 3) (Davidson, Saoud et al. 2017, Luthringer 2016, Luthringer, Pellegrini et al. 2013). Roluperidone has been reported to have low or no affinity for muscarinic, cholinergic, and histaminergic receptors, although, again, the data or methods used have not been reported (Davidson, Saoud et al. 2017).

The compound has a half-life of around 6 hours (Luthringer, Pellegrini et al. 2013). Phase I and II trials have shown that once daily dosing at 32 or 64mg is sufficient to attain a plasma concentration similar to the concentration required to elicit antipsychotic like action in rats (Luthringer, Pellegrini et al. 2013). Steady state was achieved after 7 days at dose of 1mg/kg in rats (Luthringer, Pellegrini et al. 2013). There are two main metabolites, which are reported to have similar binding profiles and similar half-lives to roluperidone. However, one metabolite had an affinity several orders of magnitude greater than roluperidone at guinea pig histamine receptors (Ki of 43.6nM) (Luthringer 2016, Ebdrup, Bjørn H., Rasmussen et al. 2011).

10.2 Clinical Efficacy

The first phase II study showed no significant benefit for roluperidone over placebo on total PANSS scores (Table 9) (Ebdrup, Bjørn H., Rasmussen et al. 2011). However, a second phase II trial showed significantly greater improvement for both 32mg and 64mg roluperidone relative to placebo on the primary outcome of endpoint of change in PANSS negative symptom factor, as well as for total PANSS score, at 12 weeks (Davidson, Saoud et al. 2017, Marder, Davis et al. 1997). Patients in the high-dose group also showed a significant improvement at 12 weeks relative to placebo in a composite cognitive score measured with the Brief Assessment of Cognition in Schizophrenia (Keefe, Harvey et al. 2018). There were significant roluperidone-associated improvements in specific domains of cognitive functioning, such as visuospatial reasoning and verbal memory (Keefe, Harvey et al. 2018).

A phase-III trial has completed recruitment, although we await a peer-reviewed publication of the results (Minerva Neurosciences Inc 2020). According to a recent presentation, there was a significant benefit of both high and low doses over placebo at 4 weeks on PANSS negative symptom factor, but this was only significant for the high dose at 8 weeks, and there was no significant effect of either dose at 12 weeks, which was the primary endpoint (Minerva Neurosciences Inc 2020). The presentation draws attention to a larger placebo effect in the phase III trial compared to the phase II trial, and to the fact that when they used the raw subscale scores for negative symptoms as an end-point, the significant benefits of high-dose treatment were sustained at 12 weeks (Minerva Neurosciences Inc 2020).

[Table 9 to appear here]

10.3 Side effect profile

Headache (7.5% vs 3.6%), asthenia (5.6% vs 2.4%), and somnolence (3.7% vs 0%) were more common in the treatment than placebo group (Davidson, Saoud et al. 2017). Not surprisingly, given the higher rates of somnolence, insomnia was less common in the treated groups compared to placebo. Side effect data was not available from the larger phase III trial (Minerva Neurosciences Inc 2020). A potential issue identified on the patent application is an increased risk of QTc prolongation with plasma concentrations over 80ng/mL, but clinical trials have so far not reported any instances of significant QTc prolongation at therapeutic doses (Luthringer, Pellegrini et al. 2013). Two patients in the phase II trial suffered serious adverse events other than relapse in schizophrenia symptoms; one had vomiting and abdominal pain and another reported syncope and bradycardia (Davidson, Saoud et al. 2017). In contrast to current antipsychotics, roluperidone has no major effects on prolactin levels or extrapyramidal side effects relative to placebo (Davidson, Saoud et al. 2017).

10.4 Summary

Encouraging effects of roluperidone on negative symptoms of schizophrenia found in initial phase II trials appear not to have been fully replicated in a larger study, although the secondary analyses may indicate an effect. The strength of these findings is not clear as the peer reviewed report has not yet been published. Roluperidone is generally well tolerated, and does not show propensity to cause extrapyramidal side effects, but detailed information on side effects from the largest study is not yet available.

**11. Ulotaront (SEP-363856)**

11.1 Pharmacology

Ulotaront (SEP-363856) is a novel antipsychotic distinctive for its agonist activity at trace amine associated receptor 1 (TAAR1; EC50=0.14μM, maximum efficacy=101.3%) (Dedic, Jones et al. 2019). An in vitro receptor screen against a panel of neuroreceptors found that ulotaront is also an agonist at the 5HT1A receptor, although its affinity is an order of magnitude lower than that for the TAAR1 (EC50=2.3μM, maximum efficacy=74.7%), and that it has lower affinity for 5-HT2A and D2 receptors (Ki=17250 and 21300 nM respectively), where ulotaront acts as a weak partial agonist (Dedic, Jones et al. 2019) (see Table 1 and Figures 1 and 3). Further in vivo testing in rat and primate brains showed that ulotaront did not produce significant D2 receptor occupancy at clinically relevant doses (Dedic, Jones et al. 2019). Therefore, any therapeutic effects are likely to be independent of a direct action on D2 receptors.

TAAR1 agonism has an inhibitory effect on the firing of dopaminergic and serotonergic neurons (Revel, Moreau et al. 2011). Further mouse studies show that ulotaront inhibits neuron firing in the ventral tegmental area of the midbrain, as well as inhibiting dorsal raphe neuronal activity via 5-HT1A agonism (Dedic, Jones et al. 2019) . Elevated striatal dopamine synthesis capacity is thought to be a key component of the pathophysiology of schizophrenia (McCutcheon, Robert, Beck et al. 2018, Brugger, Angelescu et al. 2020), and this can be reproduced in a ketamine mouse model (Kokkinou, Irvine et al. 2020b). A recent study in this ketamine mouse model shows ulotaront reduces the ketamine-induced increases in striatal dopamine synthesis capacity (Kokkinou, Irvine et al. 2020b). This suggests ulotaront may target this aspect of the pathophysiology of the disorder, in contrast to current second-generation antipsychotics (Jauhar, Veronese et al. 2019). Overall, the preclinical and pharmacological studies to date indicate that while ulotaront does not act directly on D2 receptors in vivo, it inhibits dopaminergic neuron activity, probably predominantly through TAAR1, although 5HT1A agonism may also contribute to its effects.

11.2 Clinical efficacy

There has been one randomised placebo-controlled phase II trial to date. This involved 245 participants with an acute relapse of schizophrenia. This study found a significant improvement in the ulotaront group over placebo, with a mean difference in PANSS score of -7.5 (p<0.01) over the 4-week treatment period (Table 10) (Koblan, Kent et al. 2020). The placebo response (mean change in PANSS of -9.7 at week 4) was low relative to that seen in other recent antipsychotic trials.

At the end of the 4-week trial, participants were given the option to enrol in an open-label study in which they received ulotaront (25-75mg) for 26 weeks. 156 patients (80.8% of those who completed the short-term trial) chose to participate in the extension study, 78 from the ulotaront group and 79 from the placebo group. Among the group who had initially been assigned to receive ulotaront and then continued treatment, the mean additional change in PANSS score over the 26 weeks from the start of the extension study was -17.1. Among the group who had initially received placebo and then switched to ulotaront in the extension study, the mean additional change in PANSS score from the start of the extension study was -27.9 (Koblan, Kent et al. 2020). Open-label extension treatment with ulotaront was also associated with a small improvement in cognitive performance (Milanovic, Origala et al. 2020).

Seven further trials are in progress to further assess ulotaront’s efficacy and safety (Table 10), and their results, due in the next couple of years, will be important given the small total number of participants in studies published so far. Two studies are phase III placebo-controlled RCTs assessing change in PANSS total score in patients experiencing an acute relapse of schizophrenia. Three trials are phase I studies investigating change in brain dopamine synthesis capacity, frequency of side effects and effect on QTc respectively. Two trials are phase III studies further investigating the incidence of side effects and serious adverse events in larger sample sizes.

[Table 10 to appear here]

11.3 Side effects

The adverse events that occurred during the 4-week randomised controlled trial at a frequency of at least 2% and which were more common in the ulotaront group than placebo were somnolence (6.7%), agitation (5%), nausea (5%), diarrhoea (2.5%) and dyspepsia (2.5%). The incidence of extrapyramidal symptoms was low; 3.3% in the ulotaront group and 3.2% in the placebo group (Koblan, Kent et al. 2020).

There were two serious adverse events in the ulotaront group. One of these was worsening of schizophrenia, and the second was sudden cardiac death in a patient with a history of hypertension. This patient was found to have coronary artery disease and pulmonary embolism on autopsy. There were four serious adverse events in the placebo group; three patients had worsening of schizophrenia and one attempted suicide. There was no suicidal ideation or behaviour in the ulotaront group (Koblan, Kent et al. 2020).

In the 26-week extension study, the most common adverse events were exacerbation of schizophrenia (12.2%), headache (11.5%), insomnia (8.3%), anxiety (5.1%) and somnolence (4.5%). The incidence of extra-pyramidal symptoms was similar to that in the short-term study at 3.2%. 15 of 156 patients experienced a serious adverse event; exacerbation of schizophrenia (n=11), exacerbation of psychotic disorder (n=1), acute psychosis (n=1), suicidal ideation (n=1), uterine haemorrhage (n=1) and depression (n=1). There were no deaths. Three patients reported suicidal ideation and one made an aborted attempt ((Koblan, Kent et al. 2020), supplementary appendix).

There was no clinically significant increase in metabolic laboratory values or in prolactin with ulotaront. The mean change in weight in the SEP363856 group was +0.3kg after 4 weeks and -0.32kg after 26 weeks. There was no prolongation of corrected QT interval in the short term study; in the extension study one patient showed a≥ 60msec increase in corrected QT, although no patient had a corrected QT ≥480 msec ((Koblan, Kent et al. 2020), supplementary appendix).

11.4 Summary

Ulotaront is a TAAR1 and 5HT1A agonist with a low affinity for D2 receptors. It potentially acts on the dopaminergic pathophysiology of schizophrenia by inhibiting dopaminergic neurons and reducing striatal dopamine synthesis capacity. The results of the one RCT to date showed greater improvement in the ulotaront group relative to placebo over a 4-week treatment period. One maintenance study indicated that ulotaront resulted in a sustained improvement in symptoms in patients with schizophrenia, but further long and short term studies are needed to better determine the efficacy of ulotaront as well as to investigate its efficacy compared to existing antipsychotics. Ulotaront does not appear to have a significant incidence of extrapyramidal symptoms or metabolic effects relative to placebo. The main side-effects in excess of placebo are sedation or agitation, although with a low incidence (less than 10% for each). Further safety testing in larger patient cohorts is needed to establish the incidence of rare adverse events.

**12. Xanomeline**

12.1 Pharmacology

Xanomeline is a muscarinic agonist with selectivity for M1 and M4 receptor subtypes (Ki= 79.4 nM and 20.0 nM respectively, Table 1) (Shekhar, Potter et al. 2008, Watson, Brough et al. 1998). It has the highest affinity for muscarinic receptors of novel antipsychotics discussed here (Figure 3). Some established antipsychotics including chlorpromazine, olanzapine and clozapine also bind to muscarinic receptors with similar affinity to xanomeline, but they predominantly act as antagonists at muscarinic receptors (Table 1), in contrast to xanomeline. Various evidence points to the involvement of the muscarinic cholinergic system in schizophrenia, in particular lower levels of muscarinic receptors have been found in patients with schizophrenia both post mortem and in in vivo imaging studies (McKinzie, Bymaster 2012).

Xanomeline has little affinity for dopamine receptors (Ki values for D2 and D3 receptors are 1000 and 398.1 nM respectively, Table 1), but despite this xanomeline demonstrates functional dopamine antagonism in rodent models (Shekhar, Potter et al. 2008) and has been shown to inhibit dopamine cell firing in the limbic ventral tegmental area in rodent cell recordings (Bymaster, Shannon et al. 1998). Some work has found xanomeline to have some affinity for serotonergic receptors (Ki values for 5HT1a, 5HT2a and 5HT2c receptors being 63.1, 125.9 and 39.8 nM respectively) (Roth, Lopez , Watson, Brough et al. 1998), though this was not replicated by other research groups (Felder, Bymaster et al. 2000).

There is significant first-pass metabolism of xanomeline, resulting in low oral bioavailability of <1% (Mirza, Peters et al. 2003). Following oral administration, peak plasma levels are reached after 2.5 hours (Mirza, Peters et al. 2003). Xanomeline has a half-life of 4.56 hours, with steady state thus attained 23 hours after oral administration (Bymaster, Whitesitt et al. 1997).

12.2 Clinical efficacy

Table 11 shows the two clinical trials of xanomeline in schizophrenia to date. A randomised placebo-controlled trial of xanomeline in 20 subjects with schizophrenia or schizoaffective disorder found that the xanomeline group had significantly better outcomes for total PANSS score, total BPRS score and some cognitive tests (though the statistical tests for cognition were not adjusted for multiple testing) (Shekhar, Potter et al. 2008). All subjects in this trial received placebo for the first week of the study, which may have unblinded the treatment arm if they noticed a difference in the second week of the study when they were switched from placebo to xanomeline.

A more robust, recent RCT tested the combination of xanomeline and trospium in 182 patients experiencing an acute relapse of schizophrenia over 5 weeks (Brannan, Sawchak et al. 2021). Trospium is a peripherally acting muscarinic receptor antagonist which does not cross the blood brain barrier (Rovner 2004). Therefore, the coformulation of xanomeline and trospium is hoped to result in therapeutic efficacy without peripheral cholinergic adverse effects (Brannan, Sawchak et al. 2021). Patients in the xanomeline-trospium group had significantly greater reductions in PANSS total, PANSS positive subscale and PANSS negative subscale scores compared to placebo (Brannan, Sawchak et al. 2021).

[Table 11 to appear here]

12.3 Side-effect profile

The two clinical trials of xanomeline in schizophrenia detailed above are also the only two trials of its tolerability in patients with schizophrenia. Xanomeline’s action on muscarinic receptors gives it a potential for causing a number of peripheral side effects. In the Shekhar et al trial, nausea (70%), vomiting (60%), gastrointestinal distress (70%), salivation (20%), diarrhoea (20%) and constipation (20%) were all more common in the xanomeline group compared to placebo, though this study had a small sample size of 20 (Shekhar, Potter et al. 2008).

Similarly, in their larger study of 182 subjects treated with a xanomeline-trospium combination, Brannan et al found the most common adverse events in the xanomeline-trospium group were constipation (17%), nausea (17%), dry mouth (9%) and vomiting (9%) (Brannan, Sawchak et al. 2021). This suggests that, although the addition of trospium reduces gastrointestinal effects of xanomeline, it does not abolish them. Rates of treatment discontinuation for the xanomeline-trospium combination were similar in the active treatment and control groups (20 and 21% respectively) (Brannan, Sawchak et al. 2021).

There was no significant increase in weight in the Brannan et al study for patients on xanomeline-trospium relative to placebo. While subjects in the treatment group had a peak mean increase in heart of 6.9 beats per minute at day 8 (compared to +1.4 beats per minute for the placebo group), there was no significant between-group difference in blood pressure or corrected QT. There were also similar rates of EPSEs and akathisia for the treatment and placebo groups. There were no significant differences in the incidences of sedation or agitation with xanomeline-trospium compared to placebo (Brannan, Sawchak et al. 2021). Neither the Shekhar et al nor the Brannan et al studies, nor any other trials have investigated the effect of xanomeline on serum prolactin to date.

In the Brannan et al study, one serious and one severe adverse event occurred in the xanomeline-trospium group, and one severe adverse event occurred in the treatment group. However, no further detail was given as to the nature of these (Brannan, Sawchak et al. 2021).

12.4 Summary

Xanomeline acts as a muscarinic agonist but also exhibits functional dopamine antagonism, particularly in the ventral tegmental area. An initial small RCT and a subsequent much larger RCT have both found it to be effective in alleviating positive, negative and cognitive symptoms of schizophrenia compared to placebo, though statistical tests for cognitive symptoms were not adjusted for multiple testing. While xanomeline is not associated with those adverse effects related to conventional antipsychotics such as extrapyramidal and metabolic effects, gastrointestinal side effects were relatively common. Longer term studies are needed to assess the effectiveness of xanomeline in preventing relapse, as well as further tolerability studies to determine the incidence and nature of severe adverse events.

**13. BI 409306**

13.1 Pharmacology

BI 409306 is a phosphodiesterase 9A (PDE9A) inhibitor developed to target cognitive impairment in schizophrenia and Alzheimer’s disease (Brown, Daniels et al. 2018). PDE9A hydrolyses cyclic guanosine monophosphate (cGMP) and regulates its intracellular concentration within glutamatergic neurons (Dorner-Ciossek, Kroker et al. 2017). PDE9A inhibition may thus increase intracellular cGMP availability and increase NMDA receptor signalling to enhance synaptic plasticity and memory function (Brown, Daniels et al. 2018).

BI 409306 is rapidly absorbed and eliminated. Maximum plasma concentration is reached 30-45 minutes after oral administration and its elimination half-life is 1.10 – 1.85 hours (Brown, Daniels et al. 2018).

13.2 Clinical Efficacy

There has been one phase II study of BI 409306 which did not find a significant effect of adjunctive BI 409306 on the primary outcome measure of change in MCCB (MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery) score over placebo (Table 12) (Brown, Nakagome et al. 2019). There was also no significant difference between the treatment and placebo arms for the secondary endpoints of Schizophrenia Cognition Rating Scale score or Clinical Global Impressions- Severity scale score (Brown, Nakagome et al. 2019). Two further clinical trials of BI 409306 (NCT03351244 and NCT03230097) were in progress but were terminated due to the covid-19 pandemic.

[Table 12 to appear here]

13.3 Side effect profile

PDE9A is expressed in the inner retina where cGMP regulates signalling in retinal cells (Dhingra, Tummala et al. 2014). Visual symptoms have been reported in safety studies of BI 409306 in healthy volunteers (Moschetti, Boland et al. 2016, Boland, Moschetti et al. 2017). In the phase II study in subjects with schizophrenia, eye disorders (blurred vision, photophobia, visual brightness, flashes, colour disturbance) occurred in 11.1% of participants receiving BI 409306, with a dose-dependent relationship in frequency (Brown, Nakagome et al. 2019). Other adverse events that occurred at higher rates in the treatment group with a frequency of ≥ 2% were nasopharyngitis (3.2%), nausea (2.6%) and dizziness (2.6%). No patients reported extrapyramidal side effects and rates of insomnia were similar to placebo (1.7% with BI 409306 vs 1.2% with placebo). 1.5% of participants receiving BI 409306 experienced a ‘cardiac disorder’ (compared to 1.5% of the placebo group), though none of these were classed as severe. There was no data regarding effect of BI 409306 on QTc. There were no serious adverse events in the treatment group (Brown, Nakagome et al. 2019).

13.4 Summary

BI409306 is a phosphodiesterase 9A inhibitor which has so far been tested in one short-term phase II study with no significant benefit in cognitive outcomes over placebo. Visual symptoms make up the most common reported side effects.

**14. BI 425809**

14.1 Pharmacology

Like BI409306, BI 425809 has also been developed to target cognition and memory in schizophrenia and Alzheimer’s disease (Moschetti, Schlecker et al. 2018). BI 425809 is a glycine transporter 1 (GlyT1) inhibitor that aims to target glutamatergic pathways, by increasing synaptic glycine levels to augment glutamate’s action at NMDA receptors (Moschetti, Schlecker et al. 2018).

BI 425809 reaches maximum plasma concentration between 3 and 4.5 hours after oral administration, and steady-state is reached after 6-10 days. It has a long half-life of over 30 hours (Moschetti, Schlecker et al. 2018).

14.2 Clinical efficacy

There was a statistically significant improvement on the MCCB (Measurement and Treatment Research to Improve Cognition Consensus Cognitive Battery) overall composite T-score in the BI 425809 10mg and 25mg groups of NCT02832037, though the effect sizes were small-moderate (0.34 and 0.30 for 10mg and 25mg respectively) so the clinical significance remains unclear (Table 13) (Fleischhacker, Podhorna et al. 2021). In addition, there was no statistically significant improvement in secondary outcome measures assessing social and daily functioning (Fleischhacker, Podhorna et al. 2021).

A further four clinical trials are in progress. Three phase III trials (NCT04846868, NCT04846881 and NCT04860830) will provide information regarding effect on cognitive symptoms over a longer follow-up period of 26 weeks, and one phase II trial (NCT03859973) will assess the value of combining BI 425809 and adjunctive computerised cognitive training efficacy.

[Table 13 to appear here]

14.3 Side effect profile

The most frequent adverse events reported in NCT02832037 which were more frequent for the BI 425809 treatment groups than placebo were headache (8-12% incidence for BI 425809), somnolence (2-6%) and gastrointestinal symptoms (2-11%) (Fleischhacker, Podhorna et al. 2021). Overall in the study, BI 425809 was associated with a dose-dependent decrease from baseline in haemoglobin levels and anaemia occurred in 1-5% of treatment groups. This is an expected class effect of GlyT1 inhibitors that has been reported with other glycine transporter inhibitors (Fleischhacker, Podhorna et al. 2021, Bugarski-Kirola, Dragana, Iwata et al. 2016, Bugarski-Kirola, D., Wang et al. 2014).There were no clinically relevant changes in other laboratory parameters, ocular parameters or ECG parameters. The frequency of extrapyramidal side effects was not reported, though this is not an expected adverse effect for GlyT1 inhibitors. There was no worsening of underlying disease or suicidality in the treatment arms. 3.5% of subjects receiving BI 425809 experienced a serious adverse event, compared to 2% of the placebo group. The nature of the serious adverse events were not specified further, though there were no deaths during this study (Fleischhacker, Podhorna et al. 2021).

14.4 Summary

BI 425809 is a glycine transporter 1 inhibitor increasing glutamatergic transmission. One short-term phase II study found a statistically significant improvement in cognitive outcomes with the BI 425809 10mg and 25mg over placebo, though with small effect sizes. Trials in progress will assess its efficacy over a longer follow up period and determine whether its combination with computerised cognitive training could be beneficial. Glycine transporter 1 inhibitors are associated with decrease in haemoglobin. BI 425809 appears to have a favourable metabolic profile, though longer-term data is needed.

**15. MK-8189**

15.1 Pharmacology

MK-8189 is a phosphodiesterase 10A inhibitor which modulates both dopamine D1-direct and D2-indirect striatal pathways and regulates striatal glutamate receptor phosphorylation (Krogmann, Peters et al. 2019, Grauer, Pulito et al. 2009). It therefore targets both dopaminergic and glutamatergic dysfunction thought to underlie schizophrenia.

Following oral administration, peak plasma concentration is reached between 12 and 24 hours according to data from NCT 03565068 reported on clinicaltrials.gov (not yet published) (NIH U.S. National Library of Medicine 2021).The elimination half-life of MK-8189 is between 7.6 and 10.9 hours (NIH U.S. National Library of Medicine 2021).

15.2 Clinical efficacy

There has been one clinical trial assessing clinical efficacy of 12mg MK-8189 in schizophrenia thus far (Table 14). This was conducted in patients experiencing an acute relapse and gave treatment over a 4-week period (NIH U.S. National Library of Medicine 2018). MK-8189 12mg did not show a significant difference in mean PANSS total score change relative to placebo in this relatively short study, although the active control, risperidone, did separate from placebo (NIH U.S. National Library of Medicine 2018).

A further larger phase II trial is currently underway which will test MK-8189 at higher doses of 16mg and 24mg.

[Table 14 to appear here]

15.3 Side effect profile

The results of study NCT03565068 assessing safety and tolerability of MK-8189 have not yet been published (NIH U.S. National Library of Medicine 2021).

15.4 Summary

MK-8189 is a phosphodiesterase 10A inhibitor acting on dopaminergic and glutamatergic dysfunction in schizophrenia. One short-term phase II trial did not find a significant benefit from MK-8189 12mg over placebo, though a larger study is underway testing higher doses of MK-8189. Tolerability data have not yet been published.

**16. Other compounds in development**

Ralmitaront (RO6889450) acts on the TAAR1 receptor, like SEP-363856, but as a partial agonist (Gomes, Grace 2021). Two phase II studies are currently in progress to assess the efficacy of ralmitaront on acute relapse of schizophrenia and on negative symptoms (NCT03669640 and NCT04512066) (NIH U.S. National Library of Medicine 2021c, NIH U.S. National Library of Medicine 2021e).

BIIB-104 is an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor positive allosteric modulator currently being tested in a phase II study of cognitive impairment in schizophrenia (NCT03745820) (NIH U.S. National Library of Medicine 2021d, Kadriu, Musazzi et al. 2021). The AMPA receptor is a non-NMDA type glutamate receptor thought to be involved in synaptic plasticity inherent in learning and memory (Kadriu, Musazzi et al. 2021).

Evenamide (NW-3509) is a selective voltage-gated sodium channel blocker which inhibits synaptic release of glutamate and reduces neuronal hyperexcitability in the prefrontal cortex and hippocampus (Bhatia, Goyal et al. 2019, Singh, Sharma et al. 2019). It does not interact with dopaminergic, noradrenergic, serotonergic or histaminergic neurotransmitter systems (Singh, Sharma et al. 2019). A phase II RCT found that add-on evenamide was associated with statistically significant efficacy and good tolerability (Anand, Forrest et al. 2018, Anand, Hartman et al. 2017), though full results have yet to be published.

TAK-041 is a G-protein-coupled receptor 139 (GPCR139) agonist (Reichard, Schiffer et al. 2021). GPCR 139 is highly expressed in the habenula, a brain nucleus involved in transducing information from the forebrain to dopaminergic and serotonergic systems in the midbrain and brainstem and thought to be implicated in schizophrenia (Reichard, Schiffer et al. 2021). A phase II RCT of add-on TAK-041 to existing antipsychotic treatment in 23 subjects did not find a statistically significant improvement in cognitive function with TAK-041 according to the summary online (NCT03319953) (NIH U.S. National Library of Medicine 2021b), although, as the full study report has not been published to date, it is not clear if it was powered to detect a significant difference or if further studies are planned.

ALKS-3831 was developed as a combination of olanzapine with samidorphan (an opioid antagonist) (Krogmann, Peters et al. 2019). Samidorphan binds with high affinity to μ-, κ- and δ-opioid receptors and so reduces olanzapine-induced food craving by blocking receptors in the brain reward pathway (Krogmann, Peters et al. 2019). Short-term phase II and phase III studies have shown that ALKS-3831 has similar efficacy to olanzapine alone (Martin, Correll et al. 2019, Potkin, Kunovac et al. 2020). In 12-week and 6-month studies, ALKS-3831 led to significantly less weight gain, though there was no significant difference in serum glucose and lipids relative to olanzapine (Martin, Correll et al. 2019, Krogmann, Peters et al. 2019).

**17. Conclusions**

Established antipsychotics have a number of limitations in the treatment of schizophrenia including treatment resistance in up to a third of patients, limited efficacy for negative and cognitive symptoms, and poor tolerability in many patients. Our review has identified a number of pharmacological and clinical features of new and emerging drugs that could address these issues. Key features of these drugs are reviewed in the summary table (Table 15), together with our evaluation of the strength of the corresponding evidence based on the GRADE criteria. A limitation of our approach is that we have not reviewed all drugs in development for schizophrenia. However, it is not possible to review all drugs at any stage of development. Instead, our review focuses on drugs that have recently been licensed, or are in late phase development (with at least one phase II trial on clinicaltrials.gov) to provide an update on new and emerging treatments with a range of different mechanisms. It should be recognised that there are other promising compounds in development. Nevertheless, our review has identified a number of novel pharmacological approaches to treating schizophrenia with promising clinical support. In addition, we have searched company websites and other data sources to provide additional data to complement the findings on these compounds published in scientific journals.

[Table 15 to appear here]

We identified only one drug (Lu AF35700) that has been tried in treatment resistance recently, despite the major clinical and health economic burden this represents (Kane, Agid et al. 2019, Potkin, Kane et al. 2020). Whilst Lu AF35700 did not show a benefit over olanzapine/risperidone in treatment resistance, several studies with other drugs are ongoing for this indication, notably with lumateperone and pimavanserin. Of note, long term use of established antipsychotics may contribute to late-onset treatment resistance due to D2 and D3 receptor upregulation and subsequent supersensitivity to dopamine (Potkin, Kane et al. 2020). Dopamine partial agonists (cariprazine, brexpiprazole, brilaroxazine and F17464), and indeed the other novel agents with low D2 binding, are not expected to induce D2 receptor supersensitivity and so may be associated with a lower risk of inducing secondary treatment resistance (Murray, R. M., Quattrone et al. 2016). This may be a potential benefit of these novel approaches, although it needs testing in clinical populations.

For negative symptoms, emerging evidence suggests that some of the novel agents could show promise in targeting these domains. Of these drugs, only cariprazine, pimavanserin and roluperidone have been tested in studies where the primary aim was to test efficacy for negative symptoms, and cariprazine is the only drug to date that has been tested against an established antipsychotic. Whilst cariprazine showed a benefit for negative symptoms over the established antipsychotic, confirmation of this finding is required from further large prospective studies to determine if the promising initial results are robust and clinically meaningful.

With regard to cognitive symptoms, one RCT showed high-dose roluperidone was associated with an improvement in cognition over placebo, as did another RCT testing xanomeline-trospium, though cognitive tests for the latter drug were not adjusted for multiple testing. Open-label maintenance treatment of SEP-363856 was also associated with a small improvement in cognitive performance.

BI 425809 was associated with statistically significant improvement in cognition over placebo in one RCT, but BI 409306 was not. The other novel agents have not been specifically investigated for their effects on cognition to date. Lumateperone may additionally result in improvement in depressive symptoms, although this was based on a very small sample. Nevertheless, this potential benefit of lumateperone could be very useful given the high prevalence of depressive symptoms in schizophrenia, highlighting the value of further testing.

Further work is also needed to investigate the efficacy of these new treatment options relative to well-established antipsychotics and study their long-term effectiveness preventing relapse. Preliminary findings suggest cariprazine is safe in adolescent and elderly patients, but the novel agents will all require further investigation in paediatric and elderly patient cohorts before their use is expanded to these age groups. Additional trials are currently planned to test the use of cariprazine, brexpiprazole and lumateperone in children and adolescents.

With respect to side effects, all the agents we have reviewed are notable in not being high-affinity D2 antagonists, which means that the risk of EPSE and hyperprolactinemia should be lower than that seen with established antipsychotics. Lumateperone, pimavanserin, roluperidone, SEP-363856, xanomeline, BI 409306 and F17464 appear to be particularly favourable with rates of extra-pyramidal side effects very similar to placebo. In contrast, approximately 10% of patients taking cariprazine and 6% of patients on brilaroxazine experience EPSEs, although this is still lower than rates with many established drugs (Misdrahi, Tessier et al. 2019). The incidence of extra-pyramidal side effects in BI 425809, Lu AF35700 and MK-8189 has not been reported. Prolactin elevation, and its effects on sexual function and bone mineral density, is a common side effect of established antipsychotics (Howes, Oliver D., Wheeler et al. 2005, Howes, O. 2007). F17464 was the only antipsychotic among these novel agents associated with hyperprolactinaemia. Cariprazine, brexpiprazole, lumateperone, pimavanserin, roluperidone, SEP-363856 and brilarozazine did not lead to elevated prolactin levels. There is no data yet regarding the effects of xanomeline, BI 409306, BI 425809, LuAF AF35700 and MK-8189 on serum prolactin.

Metabolic and cardiovascular side-effects are a considerable concern with many established antipsychotics, particularly second generation drugs such as clozapine and olanzapine, and given that schizophrenia may be associated with an increased risk of cardiometabolic dysregulation (Pillinger, Beck et al. 2017, Osimo, Brugger et al. 2020). Pimavanserin and roluperidone have been found to induce QTc prolongation, but neither has major effects on metabolic parameters. Cariprazine, brexpiprazole, lumateperone, SEP-363856, xanomeline, BI 425809 and brilaroxazine result in little derangement of metabolic parameters or QTc interval, suggesting these could be significant advantages over established antipsychotics. F17464 was associated with hyperlipidaemia, though not with change in ECG parameters. More data is needed regarding the cardiometabolic effects of BI 409306, Lu AF35700 and MK-8189.

Lumateperone appears to have the highest propensity to cause sedation, with this affecting a quarter of patients in short term trials, corresponding to the drug’s high affinity for 5-HT2A receptors. Somnolence was also more common in patients taking roluperidone and BI 425809 over placebo. On the other hand, cariprazine, brexpiprazole, brilaroxazine and F17464 are activating with higher rates of akathisia and restlessness than sedation, in keeping with their mechanism as partial dopamine agonists (Kaar, Natesan et al. 2020). SEP-363856 and Lu AF35700 resulted in low rates of somnolence or agitation (each affecting less than 10% of patients), and for xanomeline and BI 409306 there was no evidence of increased rates of sedation or agitation relative to placebo. The frequency of sedation and agitation with MK-8189 was not specified. It, of course, remains possible that other side effects of these novel agents may emerge with larger trials and in post-marketing experience but, notwithstanding this, their favourable profiles to date represent a significant advantage over established antipsychotics.

Finally, it is important to note the varying mechanisms of action of these novel agents. While cariprazine, brexpiprazole, lumateperone, brilaroxazine and F17464 act directly on dopamine receptors, the discoveries that pimavanserin, roluperidone, SEP-363856 and xanomeline reduce positive symptoms without acting directly on D2 receptors are important potential demonstrations that antipsychotic efficacy can be independent of direct action at D2/3 receptors. If these findings are confirmed in phase III trials in schizophrenia, this would represent a key advancement in our understanding of the pathophysiology of psychosis and opens up new avenues for future drug development based on non-D2 blocking approaches.

**References**

ABBAS, A. and ROTH, B.L., 2008. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. *Expert opinion on pharmacotherapy,* **9**(18), pp. 3251-3259.

ABBS, B., BUGARSKI-KIROLA, D., LIU, I., DARWISH, M. and STANKOVIC, S., 2020. T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT. *Schizophrenia bulletin,* **46**(Supplement\_1), pp. S247-S248.

ABI-DARGHAM, A., 2014. Schizophrenia: overview and dopamine dysfunction. *The Journal of clinical psychiatry,* **75**(11), pp. 31.

ACADIA PHARMACEUTICALS INC, 17 Jun, 2020a-last update, Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1). Available: https://clinicaltrials.gov/ct2/show/results/NCT02970292 [31 May, 2021].

ACADIA PHARMACEUTICALS INC, Jun 17, 2020b-last update, NCT02970292- Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1). Available: https://clinicaltrials.gov/ct2/show/results/NCT02970292 [Jan 26, 2021].

ACADIA PHARMACEUTICALS INC, Dec 22, 2020c-last update, NCT02970305- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE). Available: https://clinicaltrials.gov/ct2/show/NCT02970305 [Jan 26, 2021].

ACADIA PHARMACEUTICALS INC, Dec 28, 2020d-last update, NCT03121586- Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia . Available: https://clinicaltrials.gov/ct2/show/NCT03121586 [Jan 26, 2021].

ACADIA PHARMACEUTICALS INC, Nov 25, 2019a-last update, ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia. Available: https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-announces-positive-top-line-results [Jan 26, 2021].

ACADIA PHARMACEUTICALS INC, Jul 22, 2019b-last update, ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia . Available: https://www.businesswire.com/news/home/20190722005666/en/ACADIA-Pharmaceuticals-Announces-Top-line-Results-from-Phase-3-ENHANCE-Trial-of-Pimavanserin-as-Adjunctive-Treatment-for-Patients-with-Schizophrenia [Jan 26, 2021].

ACADIA PHARMACEUTICALS INC, 2016-last update, Nuplazid (pimavanserin) [package insert]. Available: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2016/207318lbl.pdf [02 Jan, 2021].

ANAND, R., FORREST, E.C., HARTMAN, R.D., GRAHAM, S.M. and FARAVELLI, L., 2018. T48. Antipsychotic efficacy of Evenamide (NW-3509) is due to modulation of glutamatergic dysregulation. Schizophrenia bulletin, 44(Suppl 1), pp. S132.

ANAND, R., HARTMAN, R., GRAHAM, S., FORREST, E. and FARAVELLI, L., 2017. 18. Evenamide, a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities to Improve Psychotic Symptoms in Patients With Schizophrenia: Results From a Phase II, Placebo-Controlled Trial. Schizophrenia bulletin, 43(Suppl 1), pp. S13.

ATACK, J. and LAVREYSEN, H., 2010-last update, Agonist [Homepage of Springer, Berlin, Heidelberg], [Online]. Available: https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1\_1565 [06 Nov, 2021].

BALTZERSEN, O.B., MELTZER, H.Y., FROKJAER, V.G., RAGHAVA, J.M., BAANDRUP, L., FAGERLUND, B., LARSSON, H.B., FIBIGER, H.C., GLENTHØJ, B.Y. and KNUDSEN, G.M., 2020. Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. *Frontiers in Pharmacology,* **11**, pp. 591.

BARABÁSSY, Á, SEBE, B., ACSAI, K., LASZLOVSZKY, I., SZATMÁRI, B., EARLEY, W.R. and NÉMETH, G., 2021. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. *Neuropsychiatric Disease and Treatment,* **17**, pp. 957.

BARNES, T.R., DRAKE, R., PATON, C., COOPER, S.J., DEAKIN, B., FERRIER, I.N., GREGORY, C.J., HADDAD, P.M., HOWES, O.D. and JONES, I., 2020. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. *Journal of Psychopharmacology,* **34**(1), pp. 3-78.

BHATIA, M.S., GOYAL, A. and PRIYADARSHINI, N.C., 2019. Evenamide–A New Hope for Treatment Resistant Schizophrenia. Delhi Psychiatry Journal, 1, pp. 171.

BITTER, I., GROC, M., DELSOL, C., FABRE, C., FAGARD, M., BARTHE, L., GAUDOUX, F., BRUNNER, V., BRACKMAN, F. and TONNER, F., 2017. Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia. European Psychiatry, 41(S1), pp. S387.

BITTER, I., LIEBERMAN, J.A., GAUDOUX, F., SOKOLOFF, P., GROC, M., CHAVDA, R., DELSOL, C., BARTHE, L., BRUNNER, V. and FABRE, C., 2019. Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology, 44(11), pp. 1917-1924.

BLAIR, H.A., 2020. Lumateperone: First Approval. *Drugs,* , pp. 1-7.

BOLAND, K., MOSCHETTI, V., DANSIRIKUL, C., PICHEREAU, S., GHEYLE, L., RUNGE, F., ZIMDAHL‐GELLING, H. and SAND, M., 2017. A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Human Psychopharmacology: Clinical and Experimental, 32(1), pp. e2569.

BRANNAN, S.K., SAWCHAK, S., MILLER, A.C., LIEBERMAN, J.A., PAUL, S.M. and BREIER, A., 2021. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. *New England Journal of Medicine,* **384**(8), pp. 717-726.

BROWN, D., DANIELS, K., PICHEREAU, S. and SAND, M., 2018. A phase Ic study evaluating the safety, tolerability, pharmacokinetics, and cognitive outcomes of BI 409306 in patients with mild-to-moderate schizophrenia. Neurology and therapy, 7(1), pp. 129-139.

BROWN, D., NAKAGOME, K., CORDES, J., BRENNER, R., GRÜNDER, G., KEEFE, R.S., RIESENBERG, R., WALLING, D.P., DANIELS, K. and WANG, L., 2019. Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial. Schizophrenia bulletin, 45(2), pp. 350-359.

BRUGGER, S.P., ANGELESCU, I., ABI-DARGHAM, A., MIZRAHI, R., SHAHREZAEI, V. and HOWES, O.D., 2020a. Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. *Biological psychiatry,* **87**(3), pp. 215-224.

BRUGGER, S.P., ANGELESCU, I., ABI-DARGHAM, A., MIZRAHI, R., SHAHREZAEI, V. and HOWES, O.D., 2020b. Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. *Biological psychiatry,* **87**(3), pp. 215-224.

BUGARSKI-KIROLA, D., NUNEZ, R., ODETALLA, R., BARI, M.A., BITTER, I., FELDMAN, P.D., LIU, I.C. and STANKOVIC, S., 2020. T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT. *Schizophrenia bulletin,* **46**(Suppl 1), pp. S247.

BUGARSKI-KIROLA, D., WANG, A., ABI-SAAB, D. and BLÄTTLER, T., 2014. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia–results from the CandleLyte study. European Neuropsychopharmacology, 24(7), pp. 1024-1036.

BUGARSKI-KIROLA, D., IWATA, N., SAMELJAK, S., REID, C., BLAETTLER, T., MILLAR, L., MARQUES, T.R., GARIBALDI, G. and KAPUR, S., 2016. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. The Lancet Psychiatry, 3(12), pp. 1115-1128.

BURRIS, K.D., MOLSKI, T.F., XU, C., RYAN, E., TOTTORI, K., KIKUCHI, T., YOCCA, F.D. and MOLINOFF, P.B., 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. *Journal of Pharmacology and Experimental Therapeutics,* **302**(1), pp. 381-389.

BYMASTER, F.P., SHANNON, H.E., RASMUSSEN, K., DELAPP, N.W., MITCH, C.H., WARD, J.S., CALLIGARO, D.O., LUDVIGSEN, T.S., SHEARDOWN, M.J. and OLESEN, P.H., 1998. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R, 6R) 6-(3-propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo [3.2. 1] octane. *European journal of pharmacology,* **356**(2-3), pp. 109-119.

BYMASTER, F.P., WHITESITT, C.A., SHANNON, H.E., DELAPP, N., WARD, J.S., CALLIGARO, D.O., SHIPLEY, L.A., BUELKE‐SAM, J.L., BODICK, N.C. and FARDE, L., 1997. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. *Drug Development Research,* **40**(2), pp. 158-170.

CANTILLON, M. and BHAT, L., 2018. Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh. Schizophrenia research, 195, pp. 581-582.

CANTILLON, M., PRAKASH, A., ALEXANDER, A., INGS, R., SWEITZER, D. and BHAT, L., 2017. Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophrenia research, 189, pp. 126-133.

CHRISTIAN, R., SAAVEDRA, L. and GAYNES, B.N., 2012. Appendix A, Tables of FDA-Approved Indications for First- and Second- Generation Antipsychotics. In: (. ROCKVILLE, ed, *Future Research Needs for First- and Second- Generation Antipsychotics for Children and Young Adults.* Available from: https://www.ncbi.nlm.nih.gov/books/NBK84656/: Agency for Healthcare Research and Quality (US), .

CHRISTOPOULOS, A., STEWART, G.D. and SEXTON, P.M., 2010-last update, Antagonist [Homepage of Springer, Berlin, Heidelberg], [Online]. Available: https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1\_691 [06 Nov, 2021].

CITROME, L., 2017. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. *Journal of clinical psychopharmacology,* **37**(2), pp. 138-147.

CITROME, L., 2013. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. *Expert opinion on drug metabolism & toxicology,* **9**(2), pp. 193-206.

CITROME, L., OTA, A., NAGAMIZU, K., PERRY, P., WEILLER, E. and BAKER, R.A., 2016. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. *International clinical psychopharmacology,* **31**(4), pp. 192-201.

CLINICALTRIALS.GOV, 29 Mar, 2016-last update, Monotherapy brexpiprazole (OPC-34712) trial in the treatment of adults with early-episode schizophrenia. Available: https://clinicaltrials.gov/ct2/show/results/NCT02013622 [02 Jan, 2021].

COOPER, H., MISHRIKY, R. and ANTOUN REYAD, A., 2020. EFFICACY AND SAFETY OF CARIPRAZINE IN ACUTE MANAGEMENT OF PSYCHIATRIC DISORDERS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. *Psychiatria Danubina,* **32**(1), pp. 36-45.

CORPONI, F., FABBRI, C., BITTER, I., MONTGOMERY, S., VIETA, E., KASPER, S., PALLANTI, S. and SERRETTI, A., 2019. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *European Neuropsychopharmacology,* **29**(9), pp. 971-985.

CORPONI, F., SERRETTI, A., MONTGOMERY, S. and FABBRI, C., 2017. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. *International clinical psychopharmacology,* **32**(6), pp. 309-318.

CORRELL, C.U., DAVIS, R.E., WEINGART, M., SAILLARD, J., O’GORMAN, C., KANE, J.M., LIEBERMAN, J.A., TAMMINGA, C.A., MATES, S. and VANOVER, K.E., 2020. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. *JAMA psychiatry,* **77**(4), pp. 349-358.

CORRELL, C.U., SKUBAN, A., HOBART, M., OUYANG, J., WEILLER, E., WEISS, C. and KANE, J.M., 2016. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. *Schizophrenia research,* **174**(1-3), pp. 82-92.

CORRELL, C.U., SKUBAN, A., OUYANG, J., HOBART, M., PFISTER, S., MCQUADE, R.D., NYILAS, M., CARSON, W.H., SANCHEZ, R. and ERIKSSON, H., 2015. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry,* **172**(9), pp. 870-880.

CORRELL, C.U., VANOVER, K.E., DAVIS, R.E., CHEN, R., SATLIN, A. and MATES, S., 2021. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. *Schizophrenia research,* **228**, pp. 198-205.

COSI, C., N’GUYEN, V., CONSUL-DENJEAN, N., AUCLAIR, A., HEUSLER, P., MARTEL, J.C., LERICHE, L., SOKOLOFF, P. and GATTI-MCARTHUR, S., 2017. F17464 a new antipsychotic with preferential D3 antagonist, 5-HT1A partial agonist properties. Neurochemical studies. European Psychiatry, 41(S1), pp. s807.

COSI, C., MARTEL, J., AUCLAIR, A.L., COLLO, G., CAVALLERI, L., HEUSLER, P., LERICHE, L., GAUDOUX, F., SOKOLOFF, P. and MOSER, P.C., 2021. Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist. European journal of pharmacology, 890, pp. 173635.

CUMMINGS, J., ISAACSON, S., MILLS, R., WILLIAMS, H., CHI-BURRIS, K., CORBETT, A., DHALL, R. and BALLARD, C., 2014. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *The Lancet,* **383**(9916), pp. 533-540.

DAVIDSON, M., SAOUD, J., STANER, C., NOEL, N., LUTHRINGER, E., WERNER, S., REILLY, J., SCHAFFHAUSER, J., RABINOWITZ, J. and WEISER, M., 2017. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. *American Journal of Psychiatry,* **174**(12), pp. 1195-1202.

DAVIS, R.E. and CORRELL, C.U., 2016. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. *null,* **16**(6), pp. 601-614.

DAVIS, R., DMITRIENKO, A., GLASS, S., KOZAUER, S., SAILLARD, J., WEINGART, M., SATLIN, A., MATES, S., CORRELL, C. and VANOVER, K., 2018. F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA. *Schizophrenia bulletin,* **44**(suppl\_1), pp. S236-S237.

DEDIC, N., JONES, P.G., HOPKINS, S.C., LEW, R., SHAO, L., CAMPBELL, J.E., SPEAR, K.L., LARGE, T.H., CAMPBELL, U.C. and HANANIA, T., 2019. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. *Journal of Pharmacology and Experimental Therapeutics,* **371**(1), pp. 1-14.

DEMJAHA, A., LAPPIN, J.M., STAHL, D., PATEL, M.X., MACCABE, J.H., HOWES, O.D., HESLIN, M., REININGHAUS, U.A., DONOGHUE, K., LOMAS, B., CHARALAMBIDES, M., ONYEJIAKA, A., FEARON, P., JONES, P., DOODY, G., MORGAN, C., DAZZAN, P. and MURRAY, R.M., 2017. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. *Psychological medicine,* **47**(11), pp. 1981-1989.

DEMYTTENAERE, K., DETRAUX, J., RACAGNI, G. and VANSTEELANDT, K., 2019. Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis. *CNS drugs,* , pp. 1-18.

DHINGRA, A., TUMMALA, S.R., LYUBARSKY, A. and VARDI, N., 2014. PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform. Frontiers in molecular neuroscience, 7, pp. 60.

DORNER-CIOSSEK, C., KROKER, K.S. and ROSENBROCK, H., 2017. Role of PDE9 in Cognition. Phosphodiesterases: CNS Functions and Diseases, , pp. 231-254.

DURGAM, S., CUTLER, A.J., LU, K., MIGLIORE, R., RUTH, A., LASZLOVSZKY, I., NÉMETH, G. and MELTZER, H.Y., 2015. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. *The Journal of clinical psychiatry,* **76**(12), pp. 1574-1582.

DURGAM, S., EARLEY, W., LI, R., LI, D., LU, K., LASZLOVSZKY, I., FLEISCHHACKER, W.W. and NASRALLAH, H.A., 2016. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *Schizophrenia research,* **176**(2-3), pp. 264-271.

DURGAM, S., EARLEY, W., LU, K., NÉMETH, G., LASZLOVSZKY, I., VOLK, S. and LITMAN, R.E., 2017. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. *International journal of clinical practice,* **71**(12), pp. e13037.

DURGAM, S., LITMAN, R.E., PAPADAKIS, K., LI, D., NÉMETH, G. and LASZLOVSZKY, I., 2016. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. *International clinical psychopharmacology,* **31**(2), pp. 61.

DURGAM, S., STARACE, A., LI, D., MIGLIORE, R., RUTH, A., NÉMETH, G. and LASZLOVSZKY, I., 2014. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. *Schizophrenia research,* **152**(2-3), pp. 450-457.

EARLEY, W., DURGAM, S., LU, K., LASZLOVSZKY, I., DEBELLE, M. and KANE, J.M., 2017. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. *International clinical psychopharmacology,* **32**(6), pp. 319.

EBDRUP, B.H., RASMUSSEN, H., ARNT, J. and GLENTHØJ, B., 2011. Serotonin 2A receptor antagonists for treatment of schizophrenia. *Expert opinion on investigational drugs,* **20**(9), pp. 1211-1223.

EDWARDS, J.B., SATLIN, A., DURGAM, S., DAVIS, R.E., CHEN, R., MATES, S. and CORRELL, C.U., 2021. Cardiometabolic Safety of Lumateperone (ITI− 007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. *CNS Spectrums,* **26**(2), pp. 152.

EUROPEAN MEDICINES AGENCY, , Summary of Product Characteristics: Cariprazine. Available: https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information\_en.pdf [02 Jan, 2021].

FELDER, C.C., BYMASTER, F.P., WARD, J. and DELAPP, N., 2000. Therapeutic opportunities for muscarinic receptors in the central nervous system. *Journal of medicinal chemistry,* **43**(23), pp. 4333-4353.

FELLNER, C., 2017. New schizophrenia treatments address unmet clinical needs. Pharmacy and Therapeutics, 42(2), pp. 130.

FLEISCHHACKER, W.W., HOBART, M., OUYANG, J., FORBES, A., PFISTER, S., MCQUADE, R.D., CARSON, W.H., SANCHEZ, R., NYILAS, M. and WEILLER, E., 2017. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. *International Journal of Neuropsychopharmacology,* **20**(1), pp. 11-21.

FLEISCHHACKER, W.W., PODHORNA, J., GRÖSCHL, M., HAKE, S., ZHAO, Y., HUANG, S., KEEFE, R.S., DESCH, M., BRENNER, R. and WALLING, D.P., 2021. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet Psychiatry, 8(3), pp. 191-201.

FORBES, A., HOBART, M., OUYANG, J., SHI, L., PFISTER, S. and HAKALA, M., 2018. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. *International Journal of Neuropsychopharmacology,* **21**(5), pp. 433-441.

GARNOCK-JONES, K.P., 2017. Cariprazine: a review in schizophrenia. *CNS drugs,* **31**(6), pp. 513-525.

GOMES, F.V. and GRACE, A.A., 2021. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. International Journal of Molecular Sciences, 22(9), pp. 4467.

GRAUER, S.M., PULITO, V.L., NAVARRA, R.L., KELLY, M.P., KELLEY, C., GRAF, R., LANGEN, B., LOGUE, S., BRENNAN, J. and JIANG, L., 2009. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 331(2), pp. 574-590.

HACKSELL, U., BURSTEIN, E.S., MCFARLAND, K., MILLS, R.G. and WILLIAMS, H., 2014. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. *Neurochemical research,* **39**(10), pp. 2008-2017.

HAKALA, M., GISLUM, M., SKUBAN, A. and MEEHAN, S., 2018. O7. 5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA. *Schizophrenia bulletin,* **44**(suppl\_1), pp. S94-S95.

HJORTHØJ, C., STÜRUP, A.E., MCGRATH, J.J. and NORDENTOFT, M., 2017. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *The Lancet Psychiatry,* **4**(4), pp. 295-301.

HOWES, O., 2007. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. *The Journal of clinical psychiatry,* **68**(3), pp. 361.

HOWES, O.D. and MURRAY, R.M., 2014. Schizophrenia: an integrated sociodevelopmental-cognitive model. *The Lancet,* **383**(9929), pp. 1677-1687.

HOWES, O.D., WHEELER, M.J., MEANEY, A., O'KEANE, V., FOGELMAN, I., BLAKE, G., MURRAY, R.M. and SMITH, S., 2005. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. *Journal of clinical psychopharmacology,* **25**(3), pp. 259.

HOWES, O.D., WHITEHURST, T., SHATALINA, E., TOWNSEND, L., ONWORDI, E.C., MAK, T.L.A., ARUMUHAM, A., O’BRIEN, O., LOBO, M. and VANO, L., 2021. The clinical significance of duration of untreated psychosis: an umbrella review and random‐effects meta‐analysis. *World Psychiatry,* **20**(1), pp. 75-95.

HUHN, M., NIKOLAKOPOULOU, A., SCHNEIDER-THOMA, J., KRAUSE, M., SAMARA, M., PETER, N., ARNDT, T., BÄCKERS, L., ROTHE, P. and CIPRIANI, A., 2019. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *The Lancet,* **394**(10202), pp. 939-951.

ISHIGOOKA, J., IWASHITA, S. and TADORI, Y., 2018. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6‐week, randomized, double‐blind, placebo‐controlled study. *Psychiatry and clinical neurosciences,* **72**(9), pp. 692-700.

IVKOVIC, J., LINDSTEN, A., GEORGE, V., ERIKSSON, H. and HOBART, M., 2019. Effect of brexpiprazole on prolactin: an analysis of short-and long-term studies in schizophrenia. *Journal of clinical psychopharmacology,* **39**(1), pp. 13.

JACKSON, A., 2010-last update, Partial Agonist [Homepage of Springer, Berlin, Heidelberg], [Online]. Available: https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1\_548 [06 Nov, 2021].

JAUHAR, S., VERONESE, M., NOUR, M.M., ROGDAKI, M., HATHWAY, P., NATESAN, S., TURKHEIMER, F., STONE, J., EGERTON, A. and MCGUIRE, P., 2019. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. *Biological psychiatry,* **85**(1), pp. 79-87.

KAAR, S.J., NATESAN, S., MCCUTCHEON, R. and HOWES, O.D., 2020. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. *Neuropharmacology,* **172**, pp. 107704.

KADRIU, B., MUSAZZI, L., JOHNSTON, J.N., KALYNCHUK, L.E., CARUNCHO, H.J., POPOLI, M. and ZARATE JR, C.A., 2021. Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road. Drug discovery today, .

KANE, J.M., AGID, O., BALDWIN, M.L., HOWES, O., LINDENMAYER, J., MARDER, S., OLFSON, M., POTKIN, S.G. and CORRELL, C.U., 2019. Clinical guidance on the identification and management of treatment-resistant schizophrenia. *The Journal of clinical psychiatry,* **80**(2), pp. 0.

KANE, J.M., SKUBAN, A., HOBART, M., OUYANG, J., WEILLER, E., WEISS, C. and CORRELL, C.U., 2016. Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. *Schizophrenia research,* **174**(1-3), pp. 93-98.

KANE, J.M., SKUBAN, A., OUYANG, J., HOBART, M., PFISTER, S., MCQUADE, R.D., NYILAS, M., CARSON, W.H., SANCHEZ, R. and ERIKSSON, H., 2015. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. *Schizophrenia research,* **164**(1-3), pp. 127-135.

KANE, J.M., VANOVER, K.E., DURGAM, S., DAVIS, R., SATLIN, A., ROWE, W., MATES, S. and TAMMINGA, C., 2020. 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. *CNS spectrums,* **25**(2), pp. 316-317.

KANE, J.M., ZUKIN, S., WANG, Y., LU, K., RUTH, A., NAGY, K., LASZLOVSZKY, I. and DURGAM, S., 2015. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. *Journal of clinical psychopharmacology,* **35**(4), pp. 367-373.

KEEFE, R.S., HARVEY, P.D., KHAN, A., SAOUD, J.B., STANER, C., DAVIDSON, M. and LUTHRINGER, R., 2018. Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. *The Journal of clinical psychiatry,* **79**(3), pp. 0.

KISHI, T., IKUTA, T., MATSUDA, Y., SAKUMA, K. and IWATA, N., 2020. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. *Psychopharmacology,* , pp. 1-12.

KISS, B., HORVATH, A., NEMETHY, Z., SCHMIDT, E., LASZLOVSZKY, I., BUGOVICS, G., FAZEKAS, K., HORNOK, K., OROSZ, S. and GYERTYAN, I., 2010. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile. *Journal of Pharmacology and Experimental Therapeutics,* **333**(1), pp. 328-340.

KISS, B., HORVÁTH, A., NÉMETHY, Z., SCHMIDT, É, LASZLOVSZKY, I., BUGOVICS, G., FAZEKAS, K., HORNOK, K., OROSZ, S. and GYERTYÁN, I., 2010. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile. *Journal of Pharmacology and Experimental Therapeutics,* **333**(1), pp. 328-340.

KITTEN, A.K., HALLOWELL, S.A., SAKLAD, S.R. and EVOY, K.E., 2018. Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis. *Innovations in clinical neuroscience,* **15**(1-2), pp. 16.

KOBLAN, K.S., KENT, J., HOPKINS, S.C., KRYSTAL, J.H., CHENG, H., GOLDMAN, R. and LOEBEL, A., 2020. A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia. *New England Journal of Medicine,* **382**(16), pp. 1497-1506.

KOKKINOU, M., IRVINE, E.E., BONSALL, D.R., NATESAN, S., WELLS, L.A., SMITH, M., GLEGOLA, J., PAUL, E.J., TOSSELL, K. and VERONESE, M., 2020a. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. *Molecular psychiatry,* , pp. 1-15.

KOKKINOU, M., IRVINE, E.E., BONSALL, D.R., NATESAN, S., WELLS, L.A., SMITH, M., GLEGOLA, J., PAUL, E.J., TOSSELL, K. and VERONESE, M., 2020b. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. *Molecular psychiatry,* , pp. 1-15.

KRAUSE, M., ZHU, Y., HUHN, M., SCHNEIDER-THOMA, J., BIGHELLI, I., NIKOLAKOPOULOU, A. and LEUCHT, S., 2018. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. *European archives of psychiatry and clinical neuroscience,* **268**(7), pp. 625-639.

KROGMANN, A., PETERS, L., VON HARDENBERG, L., BÖDEKER, K., NÖHLES, V.B. and CORRELL, C.U., 2019. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS spectrums, 24(S1), pp. 38-69.

LALLY, J., AJNAKINA, O., DI FORTI, M., TROTTA, A., DEMJAHA, A., KOLLIAKOU, A., MONDELLI, V., MARQUES, T.R., PARIANTE, C. and DAZZAN, P., 2016. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychological medicine,* **46**(15), pp. 3231-3240.

LAO, K.S., HE, Y., WONG, I.C., BESAG, F.M. and CHAN, E.W., 2016. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. *CNS drugs,* **30**(11), pp. 1043-1054.

LEUCHT, S., CIPRIANI, A., SPINELI, L., MAVRIDIS, D., ÖREY, D., RICHTER, F., SAMARA, M., BARBUI, C., ENGEL, R.R. and GEDDES, J.R., 2013a. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *The Lancet,* **382**(9896), pp. 951-962.

LEUCHT, S., CIPRIANI, A., SPINELI, L., MAVRIDIS, D., ÖREY, D., RICHTER, F., SAMARA, M., BARBUI, C., ENGEL, R.R. and GEDDES, J.R., 2013b. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *The Lancet,* **382**(9896), pp. 951-962.

LIEBERMAN, J.A., DAVIS, R.E., CORRELL, C.U., GOFF, D.C., KANE, J.M., TAMMINGA, C.A., MATES, S. and VANOVER, K.E., 2016. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. *Biological psychiatry,* **79**(12), pp. 952-961.

LUTHRINGER, R., 2016. *Compositions and methods for treating schizophrenia.* United States of America: .

LUTHRINGER, R., PELLEGRINI, L. and KARABELAS, A., 2013. *Methods of use of cyclic amide derivatives to treat schizophrenia.* European Patent Office: .

MAEDA, K., SUGINO, H., AKAZAWA, H., AMADA, N., SHIMADA, J., FUTAMURA, T., YAMASHITA, H., ITO, N., MCQUADE, R.D. and MØRK, A., 2014. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. *Journal of Pharmacology and Experimental Therapeutics,* **350**(3), pp. 589-604.

MARDER, S.R., DAVIS, J.M. and CHOUINARD, G., 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. *The Journal of clinical psychiatry,* .

MARDER, S.R., ERIKSSON, H., ZHAO, Y. and HOBART, M., 2020. Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. *Acta neuropsychiatrica,* **32**(3), pp. 153-158.

MARDER, S.R., HAKALA, M.J., JOSIASSEN, M.K., ZHANG, P., OUYANG, J., WEILLER, E., WEISS, C. and HOBART, M., 2017. Brexpiprazole in patients with schizophrenia: overview of short-and long-term phase 3 controlled studies. *Acta neuropsychiatrica,* **29**(5), pp. 278-290.

MARKHAM, A., 2016. Pimavanserin: first global approval. *Drugs,* **76**(10), pp. 1053-1057.

MARTIN, W.F., CORRELL, C.U., WEIDEN, P.J., JIANG, Y., PATHAK, S., DIPETRILLO, L., SILVERMAN, B.L. and EHRICH, E.W., 2019. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. American Journal of Psychiatry, 176(6), pp. 457-467.

MAURI, M.C., PALETTA, S., DI PACE, C., REGGIORI, A., CIRNIGLIARO, G., VALLI, I. and ALTAMURA, A.C., 2018. Clinical pharmacokinetics of atypical antipsychotics: an update. *Clinical pharmacokinetics,* **57**(12), pp. 1493-1528.

MCCUTCHEON, R.A., KRYSTAL, J.H. and HOWES, O.D., 2020. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. *World Psychiatry,* **19**(1), pp. 15-33.

MCCUTCHEON, R.A., MARQUES, T.R. and HOWES, O.D., 2020. Schizophrenia—an overview. *JAMA psychiatry,* **77**(2), pp. 201-210.

MCCUTCHEON, R., BECK, K., JAUHAR, S. and HOWES, O.D., 2018a. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. *Schizophrenia bulletin,* **44**(6), pp. 1301-1311.

MCCUTCHEON, R., BECK, K., JAUHAR, S. and HOWES, O.D., 2018b. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. *Schizophrenia bulletin,* **44**(6), pp. 1301-1311.

MCKINZIE, D.L. and BYMASTER, F.P., 2012. Muscarinic mechanisms in psychotic disorders. *Novel Antischizophrenia Treatments,* , pp. 233-265.

MEADE, N., SHI, L., MEEHAN, S.R., WEISS, C. and ISMAIL, Z., 2020. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short-and long-term studies. *Journal of Psychopharmacology,* **34**(8), pp. 829-838.

MELTZER, H.Y., MILLS, R., REVELL, S., WILLIAMS, H., JOHNSON, A., BAHR, D. and FRIEDMAN, J.H., 2010. Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. *Neuropsychopharmacology,* **35**(4), pp. 881-892.

MEYER, J.M., 2020. Lumateperone for schizophrenia. *Current Psychiatry,* **19**(2), pp. 33-39.

MILANOVIC, S., ORIGALA, A., DWORAK, H., HOPKINS, S. and KOBLAN, K., 2020. M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856. *Schizophrenia bulletin,* **46**(Suppl 1), pp. S215.

MINERVA NEUROSCIENCES INC, May 29, 2020-last update, Roluperidone: Topline results from the Phase 3 trial: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 40-Week Open-Label Extension. Available: http://ir.minervaneurosciences.com/static-files/215190cc-8124-4040-b6ae-4fb52ea6578c [Jan 26, 2021].

MIRZA, N.R., PETERS, D. and SPARKS, R.G., 2003. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. *CNS drug reviews,* **9**(2), pp. 159-186.

MISDRAHI, D., TESSIER, A., DAUBIGNEY, A., MEISSNER, W.G., SCHURHOFF, F., BOYER, L., GODIN, O., BULZACKA, E., AOUIZERATE, B. and ANDRIANARISOA, M., 2019. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort. *The Journal of clinical psychiatry,* **80**(1), pp. 0.

MIZUNO, Y., MCCUTCHEON, R.A., BRUGGER, S.P. and HOWES, O.D., 2020. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. *Neuropsychopharmacology,* **45**(4), pp. 622-631.

MOSCHETTI, V., BOLAND, K., FEIFEL, U., HOCH, A., ZIMDAHL‐GELLING, H. and SAND, M., 2016. First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. British journal of clinical pharmacology, 82(5), pp. 1315-1324.

MOSCHETTI, V., SCHLECKER, C., WIND, S., GOETZ, S., SCHMITT, H., SCHULTZ, A., LIESENFELD, K., WUNDERLICH, G. and DESCH, M., 2018. Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, phase I study investigating safety and pharmacokinetics. Clinical drug investigation, 38(8), pp. 737-750.

MURRAY, C.J., VOS, T., LOZANO, R., NAGHAVI, M., FLAXMAN, A.D., MICHAUD, C., EZZATI, M., SHIBUYA, K., SALOMON, J.A. and ABDALLA, S., 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The lancet,* **380**(9859), pp. 2197-2223.

MURRAY, R.M., QUATTRONE, D., NATESAN, S., VAN OS, J., NORDENTOFT, M., HOWES, O., DI FORTI, M. and TAYLOR, D., 2016. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? *The British Journal of Psychiatry,* **209**(5), pp. 361-365.

NASRALLAH, H.A., EARLEY, W., CUTLER, A.J., WANG, Y., LU, K., LASZLOVSZKY, I., NÉMETH, G. and DURGAM, S., 2017. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. *BMC psychiatry,* **17**(1), pp. 305.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, (UK), , Treatment summary: Psychoses and related disorders. Available: https://bnf.nice.org.uk/treatment-summary/psychoses-and-related-disorders.html [09 Mar, 2021].

NÉMETH, G., LASZLOVSZKY, I., CZOBOR, P., SZALAI, E., SZATMÁRI, B., HARSÁNYI, J., BARABÁSSY, Á, DEBELLE, M., DURGAM, S. and BITTER, I., 2017. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. *The Lancet,* **389**(10074), pp. 1103-1113.

NERKAR, A.G. and BHISE, S.B., Polypharmacological Drugs in Treatment of Schizophrenia.

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 29 Mar, 2021a-last update, NCT 03565068: A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants. Available: https://clinicaltrials.gov/ct2/show/NCT03565068?term=NCT+03565068&draw=2&rank=1 [16 Oct, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 19 Mar, 2021b-last update, NCT03319953: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia. Available: https://clinicaltrials.gov/ct2/show/NCT03319953 [06 Nov, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 18 Oct, 2021c-last update, NCT03669640: A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms. Available: https://clinicaltrials.gov/ct2/show/NCT03669640 [06 Nov, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 1 Sep, 2021d-last update, NCT03745820: A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY). Available: https://clinicaltrials.gov/ct2/show/NCT03745820 [06 Nov, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 28 Oct, 2021e-last update, NCT04512066: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder. Available: https://clinicaltrials.gov/ct2/show/NCT04512066 [06 Nov, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 12 May, 2020a-last update, NCT02333487: Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700. Available: https://clinicaltrials.gov/ct2/show/NCT02333487 [21 Oct, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 26 Oct, 2020b-last update, NCT02892422: Flexible-dose, long-term safety study of Lu AF35700 in adult patients with schizophrenia (Debut) . Available: https://clinicaltrials.gov/ct2/show/NCT02892422?term=NCT02892422&draw=2&rank=1 [21 Oct, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 1 Jan, 2020c-last update, NCT03230864: Efficacy of Lu AF35700 in Patients with Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew). Available: https://clinicaltrials.gov/ct2/show/NCT03230864?term=NCT03230864&draw=2&rank=1 [21 Oct, 2021].

NIH U.S. NATIONAL LIBRARY OF MEDICINE, 26 Dec, 2018-last update, NCT03055338: An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia. Available: https://clinicaltrials.gov/ct2/show/NCT03055338?term=NCT03055338&draw=2&rank=1 [16 Oct, 2021].

NORDSTROM, A., MANSSON, M., JOVANOVIC, H., KARLSSON, P., HALLDIN, C., FARDE, L., VANOVER, K.E., HACKSELL, U., BRANN, M.R. and DAVIS, R.E., 2008. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. *International Journal of Neuropsychopharmacology,* **11**(2), pp. 163-171.

OSIMO, E.F., BRUGGER, S.P., DE MARVAO, A., PILLINGER, T., WHITEHURST, T., STATTON, B., QUINLAN, M., BERRY, A., COOK, S.A. and O'REGAN, D.P., 2020. Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study. *The British Journal of Psychiatry,* **217**(2), pp. 450-457.

PATEL, K.R., CHERIAN, J., GOHIL, K. and ATKINSON, D., 2014. Schizophrenia: overview and treatment options. *Pharmacy and Therapeutics,* **39**(9), pp. 638.

PILLINGER, T., BECK, K., STUBBS, B. and HOWES, O.D., 2017. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. *The British Journal of Psychiatry,* **211**(6), pp. 339-349.

PILLINGER, T., D’AMBROSIO, E., MCCUTCHEON, R. and HOWES, O.D., 2019. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. *Molecular psychiatry,* **24**(6), pp. 776-794.

PILLINGER, T., MCCUTCHEON, R.A., VANO, L., MIZUNO, Y., ARUMUHAM, A., HINDLEY, G., BECK, K., NATESAN, S., EFTHIMIOU, O., CIPRIANI, A. and HOWES, O.D., 2020a. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *The Lancet Psychiatry,* **7**(1), pp. 64-77.

PILLINGER, T., MCCUTCHEON, R.A., VANO, L., MIZUNO, Y., ARUMUHAM, A., HINDLEY, G., BECK, K., NATESAN, S., EFTHIMIOU, O. and CIPRIANI, A., 2020b. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *The Lancet Psychiatry,* **7**(1), pp. 64-77.

POTKIN, S.G., KANE, J.M., CORRELL, C.U., LINDENMAYER, J., AGID, O., MARDER, S.R., OLFSON, M. and HOWES, O.D., 2020. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ schizophrenia,* **6**(1), pp. 1-10.

POTKIN, S.G., KUNOVAC, J., SILVERMAN, B.L., SIMMONS, A., JIANG, Y., DIPETRILLO, L. and MCDONNELL, D., 2020. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. The Journal of clinical psychiatry, 81(2), pp. 0.

RANCANS, E., DOMBI, Z.B., MÁTRAI, P., BARABÁSSY, Á, SEBE, B., SKRIVELE, I. and NÉMETH, G., 2021. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. *International clinical psychopharmacology,* **36**(3), pp. 154.

REICHARD, H.A., SCHIFFER, H.H., MONENSCHEIN, H., ATIENZA, J.M., CORBETT, G., SKAGGS, A.W., COLLIA, D.R., RAY, W.J., SERRATS, J. and BLIESATH, J., 2021. Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia. Journal of medicinal chemistry, 64(15), pp. 11527-11542.

REVEL, F.G., MOREAU, J., GAINETDINOV, R.R., BRADAIA, A., SOTNIKOVA, T.D., MORY, R., DURKIN, S., ZBINDEN, K.G., NORCROSS, R. and MEYER, C.A., 2011. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. *Proceedings of the national academy of sciences,* **108**(20), pp. 8485-8490.

REYAD, A.A. and MISHRIKY, R., 2019. Cariprazine: Pharmacology and Use in the Clinical Management of Psychiatric Disorders. *Psychiatric Annals,* **49**(3), pp. 129-134.

ROBINSON, D., WOERNER, M.G., ALVIR, J.M.J., BILDER, R., GOLDMAN, R., GEISLER, S., KOREEN, A., SHEITMAN, B., CHAKOS, M. and MAYERHOFF, D., 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Archives of General Psychiatry,* **56**(3), pp. 241-247.

ROTH, B. and LOPEZ, E., , PDSP Ki Database. Available: https://pdsp.unc.edu/databases/kidb.php [02 Jan, 2021].

ROVNER, E.S., 2004. Trospium chloride in the management of overactive bladder. *Drugs,* **64**(21), pp. 2433-2446.

SATLIN, A., VANOVER, K. and DURGAM, S., 2019Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia [abstract no. W203 plus poster], *58th Annual Meeting of the American College of Neuropsychopharmacology* 2019.

SATLIN, A., DURGAM, S., VANOVER, K.E., DAVIS, R.E., HUO, J., MATES, S. and CORRELL, C., 2020. M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. *Schizophrenia bulletin,* **46**(Supplement\_1), pp. S214.

SELVARAJ, S., ARNONE, D., CAPPAI, A. and HOWES, O., 2014. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. *Neuroscience & Biobehavioral ReviewsF,* **45**, pp. 233-245.

SHEKHAR, A., POTTER, W.Z., LIGHTFOOT, J., LIENEMANN D PHARM, J., DUBÉ, S., MALLINCKRODT, C., BYMASTER, F.P., MCKINZIE, D.L. and FELDER, C.C., 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. *American Journal of Psychiatry,* **165**(8), pp. 1033-1039.

SIEMIENIUK, R. and GUYATT, G., 2019-last update, What is GRADE. Available:

https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/ [06 Nov, 2021].

SINGH, R., SHARMA, R., KUMAR, B., KUHAD, A., GAJDOSIK, Z., CHOWDARY, P., PERALTA, R.M., TORRAMADE, E., MOLAS, G. and TELL, M., 2019. Evenamide hydrochloride. Voltage-gated sodium channel blocker, Treatment of schizophrenia. DRUGS OF THE FUTURE, 44(9), pp. 693-698.

SLIFSTEIN, M., ABI-DARGHAM, A., GIRGIS, R.R., SUCKOW, R.F., COOPER, T.B., DIVGI, C.R., SOKOLOFF, P., LERICHE, L., CARBERRY, P. and OYA, S., 2020. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11 C]-( )-PHNO. Psychopharmacology, 237(2), pp. 519-527.

SLIFSTEIN, M., 2010-last update, Affinity [Homepage of Springer, Berlin, Heidelberg], [Online]. Available: https://link.springer.com/referenceworkentry/10.1007/978-3-540-68706-1\_791 [06 Nov, 2021].

SLIFSTEIN, M., VAN DE GIESSEN, E., VAN SNELLENBERG, J., THOMPSON, J.L., NARENDRAN, R., GIL, R., HACKETT, E., GIRGIS, R., OJEIL, N. and MOORE, H., 2015. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA psychiatry,* **72**(4), pp. 316-324.

SMULEVICH, A.B., IVANOV, S.V., YAKHIN, K.K., VORONOVA, E.I., KHARKOVA, G.S., SKURYGINA, E.I., KONOHOVA, M.V., BEYBALAEVA, T.Z. and KATOK, A.A., 2020. Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study). *Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova,* **120**(12), pp. 67-72.

SNYDER, G.L., VANOVER, K.E., ZHU, H., MILLER, D.B., O’CALLAGHAN, J.P., TOMESCH, J., LI, P., ZHANG, Q., KRISHNAN, V. and HENDRICK, J.P., 2015. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. *Psychopharmacology,* **232**(3), pp. 605-621.

SOKOLOFF, P. and LE FOLL, B., 2017. The dopamine D3 receptor, a quarter century later. European Journal of Neuroscience, 45(1), pp. 2-19.

STAHL, S.M., 2017. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. *CNS spectrums,* **22**(5), pp. 375-384.

STEWART, G.D., SEXTON, P.M. and CHRISTOPOULOS, A., 2010-last update, Inverse Agonists [Homepage of Springer, Berlin, Heidelberg], [Online]. Available: https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1\_297 [06 Nov, 2021].

SZATMÁRI, B., BARABÁSSY, Á, HARSÁNYI, J., LASZLOVSZKY, I., SEBE, B., GÁL, M., SHIRAGAMI, K. and NÉMETH, G., 2020. Cariprazine safety in adolescents and the elderly: Analyses of clinical study data. *Frontiers in psychiatry,* **11**.

TADORI, Y., FORBES, R.A., MCQUADE, R.D. and KIKUCHI, T., 2011. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. *European journal of pharmacology,* **668**(3), pp. 355-365.

TAYLOR, D.M., BARNES, T.R.E. and YOUNG, A.H., 2018. Schizophrenia and related psychoses. *The Maudsley Prescribing Guidelines in Psychiatry, 13th Edition.* Hoboken, USA: Wiley Blackwell, pp. 3-203.

TENJIN, T., MIYAMOTO, S., NINOMIYA, Y., KITAJIMA, R., OGINO, S., MIYAKE, N. and YAMAGUCHI, N., 2013. Profile of blonanserin for the treatment of schizophrenia. *Neuropsychiatric disease and treatment,* **9**, pp. 587.

U.S. FOOD AND DRUG ADMINISTRATION, Dec, 2019-last update, Calypta Prescribing Information. Available: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2019/209500s000lbl.pdf [30 Dec, 2020].

USIELLO, A., BAIK, J., ROUGÉ-PONT, F., PICETTI, R., DIERICH, A., LEMEUR, M., PIAZZA, P.V. and BORRELLI, E., 2000. Distinct functions of the two isoforms of dopamine D2 receptors. *Nature,* **408**(6809), pp. 199-203.

VANOVER, K.E., DAVIS, R.E., ZHOU, Y., YE, W., BRAŠIĆ, J.R., GAPASIN, L., SAILLARD, J., WEINGART, M., LITMAN, R.E. and MATES, S., 2019. Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. *Neuropsychopharmacology,* **44**(3), pp. 598-605.

VANOVER, K., DMITRIENKO, A., GLASS, S., KOZAUER, S., SAILLARD, J., WEINGART, M., SATLIN, A., MATES, S., CORRELL, C. and DAVIS, R., 2018. S44. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study. *Schizophrenia bulletin,* **44**(suppl\_1), pp. S341.

VOS, T., ALLEN, C., ARORA, M., BARBER, R.M., BHUTTA, Z.A., BROWN, A., CARTER, A., CASEY, D.C., CHARLSON, F.J. and CHEN, A.Z., 2016. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The lancet,* **388**(10053), pp. 1545-1602.

WATSON, J., BROUGH, S., COLDWELL, M.C., GAGER, T., HO, M., HUNTER, A.J., JERMAN, J., MIDDLEMISS, D.N., RILEY, G.J. and BROWN, A.M., 1998. Functional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors. *British journal of pharmacology,* **125**(7), pp. 1413-1420.

WEBSTER, P., 2018. Pimavanserin evaluated by the FDA. *The Lancet,* **391**(10132), pp. 1762.

ZHANG, L. and HENDRICK, J.P., 2018. The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. *Matters,* **4**(3), pp. e201712000006.

ZHAO, M., QIN, B., WANG, J., ZHANG, Y., ZHAO, J., MAO, Y., ZHANG, X. and ZHANG, R., 2018. Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials. *Journal of clinical psychopharmacology,* **38**(1), pp. 55-59.

**Figure captions**

Figure 1: 1/Ki values for new and representative established antipsychotics. Established antipsychotics are all bind to D2 receptors, whereas several newer antipsychotics have no appreciable affinity for D2 receptors.

Figure 2: 1/ Ki values relative to D2 Ki for new and well-established antipsychotics. There is wide variation between antipsychotics in their affinities for other receptors relative to their affinities for the D2 receptor.

Figure 3: Web diagrams showing receptor affinities for new and well-established antipsychotics. Each antipsychotic has a distinct receptor binding profile. The numbers on the concentric lines represent the affinity (Ki) of a drug for that receptor where 4 = very high affinity (Ki <1 nM), 3 = high affinity (Ki 1- 10 nM), 2 = moderate affinity (Ki 10 – 100 nM), 1 = low affinity (Ki 100 – 1000 nM) and 0 = very low affinity (Ki > 1000 nM).